





## **OWNERSHIP STATEMENT**

This document, the data contained in it and copyright therein are owned by Bayer CropScience. No part of the document or any information contained therein may be disclosed to any third party without the prior written authorisation of Bayer CropScience

The summaries and evaluations contained in this document are based on unpublished proprietary data submitted for the purpose of the assessment undertaken by the regulatory authority. Other registration authorities should not grant, amend, or renew a registration on the supposed proprietary, data, contained in this
 from Bayer CropScience; or
 from other applicants once the period of data protection has expired? basis of the summaries and evaluation of inpublished proprietary data contained in this document unless they have received the data on which the summaries and evaluation are based, either:

## Version history

Date (yyyy-mm-dd)	Data points containing amendments or additions <sup>1</sup> and brief description	Document identifier and version number
2015-09-14	Original Document MCP – Section 7 of Supplementary Dossier	M-533250-0,12A 💍
<mark>2016-05-03</mark>	Dossier update according to "Request for additional information of the supplementary dossier submitted by Bayer CronScience for the	M-533250-02-1
	approval renewal of the active substance Fosetyl (2015-5865) by	
	RMS France on 2016-04-04:         S           - The evaluation of the exposure of bystanders and residents	
	using the new EFSA calculator has been added to mapters CP 7.2.2 and CP 7.2.2.1 and as Table 2.2.2 and Table 7.2.2.1-4.	
2016-11-14	Dossier update according to "Request for additional information of	M-533250-03-1
	the supplementary dossier submitted by Bayer CropScience for the approval renewal of the active substance Fosets J (2015-3865) by	
	RMS France on 2016-04-04: 0	Y L A
	- Study KCP 7.3/01, <b>1999</b> , M.; <b>2015</b> ; M251285&01-1, has been, amended new study report: <b>2016</b> , M-512858-02.0	
<sup>1</sup> It is suggested the	at applicants adopt a spailar approach to showing revisions and versions	on history as outlined in
SANCO/10180/2	013 Chapter 4 "How to revise an Assessment Report	S. S.
		Č, <sup>v</sup> y



## **Table of Contents**



## CP 7 TOXICOLOGICAL STUDIES ON THE PLANT PROTECTION PRODUCT

Fosetyl was included in Annex I to Directive 91/414/EEC in 2006 (Directive 2006/64/CE of 18 July 2006, Entry into Force on 1 May 2007). This Supplementary Dossier contains only data which were not submitted at the time of the Annex I inclusion of fosetyl under Directive 91/414/EEC and which were therefore not evaluated during the first EU review. All data which were already submitted by Bayer CropScience (BCS) for the Annex I inclusion under Directive 91/414/EEC are contained in the DAR, its Addenda and are included in the Baseline Dossier provided by BCS. These data are only mentioned in the Supplementary Dossier for the sake of completeness and only general information (e.g. author, reference etc.) is available for these data. In order to facturate discrimination betweet new data and data submitted during the Annex I inclusion process under Directive 91/414/EEC the of data are written in grey typeface. For all new studies, detailed summaries are provided within this Supplementary Dossier. Additional information requested by the RMS France on 2016-04-04 during the evaluation of the Supplementary Dossier is fughlighted in yellow. Additional information requested by the RMS France on 2016-11-14 during the evaluation of the Supplementary Dossier is highlighted in grey.

Fosetyl is the ISO common name for ethyl hydrogen phosphonate (IUPAC) hot the atuminum salt fosetyl-aluminium (fosetyl-Al), a variant of posetyl is used in the formulated product

The formulation Fosetyl-Al + Eluopiconde WG 71.16 (FEA + FLC WG F1.11) is a water dispersible granule (WG) formulation containing 666.7 g/kg of fosetyl-Al and 44.4 g/kg of floopicolide. This formulation is registered throughout Europe mader made manes such as Profiler. FEA + FLC WG 71.11 was not a representative formulation for the Annex I inclusion of fosetyl under Directive 91/414/EEC but has been evaluated as the representative formulation for the Annex I inclusion of fluopicolide under Directive 91/414/EEC.

## **CP 7.1**

Fosetyl-Al + Fluopicolide WG 71.11 (FEA, + FLC, WG 6.11) bas a very low acute oral and percutaneous toxicity in male and female rats.

Assute to xicity

An acute inhalation study has previously not been required for products containing only non-volatile active substances if they are not dusty with a significant proportion of inhalable particles or applied by spraying generating inhalable particles. Thus, no active inhalation study has been conducted with FEA + FLC WG  $\gtrsim$  1.11. The current data requirements for plant protection products, however, stipulate that acute inhalation studies should be performed with all products that are applied by spraying, such as FEA + FLO WG  $\ll$  1.11.

Since neither the active Substances now any of the co-formulants in FEA + FLC WG 71.11 are classified for acute Sinhalation toxicity, the calculation method laid down in Annex I, Section 3.1.3.6.2.3 of Regulation r272/2008 is applied. The Acute Toxicity Estimate for the inhalation toxicity of FEA + FLC WG 71.11 therefore does not require a classification for acute inhalation toxicity.

classification for acute initialation toxicity. FEA + FLC WC 71.11 is initiating to eyes but not to skin. It has no skin-sensitizing potential (see Table 7.1-10

## Table 7.1- 1:Acute toxicity studies with FEA + FLC WG 71.11

Study Type	Species	Results	Reference 🔊 🥎
Acute oral toxicity		$LD_{50} = 5000 \text{ mg/kg bw} (\bigcirc + \bigcirc)$	; 2003; 220866-01-10
Acute dermal toxicity	Rat	LD <sub>50</sub> > 2000 mg/kg bw (♂+♀)℃	; ) 2003; M-220872-02- 1
Acute inhalation toxicity	_	No study ATE = 9 mg/L calculation method	
Skin irritation	Dabbit	Noterritating	; <b>20</b> 02; <b>%</b> M-223952-04-1
Eye irritation	Rabbit	Eye irritant (reversible effects), Eye Irrit. 2, H219	; 2003; <sup>y</sup> N-223965-01-1
Skin sensitisation (Modified Buehler Test, nine induction applications)	Guinea pig	New sensitizing	22003; MQ23976001-1
CP 7.1.1 Oral toxicity			
Report: KCP 7. 21/0	)1	2003; @-220868-01-1° ~	) «
Title: Study for ac	ute oral toxici	ty in rats Code: AF@r053606 06 WG7	/1 A©(EXP11074B)
Report No.: C036522			, Q
Document No.: $M=220866$			
Guideline(s): $EU (= EEC)$	196/54/EECA	Innex V B, Bart B, B.1; OECD: 4253	USEPA (=EPA):
Cuidalina daviation(a)			
CL D/CED.	× ~~ '		
GLP/GEP:	´ * <sup>0</sup> ` _~		
Executive Suppary			
A study for soute off toxisty in a	male and fem	A Witter rate was conducted wi	ith the test substance
A E E05361 06 WG71 A1 EXPIT	074 EFA	FIC WG The 11) The study was	conducted according
to the Age Toxic Cloc Mathed	OF AN Cuida	line 122) Weter and as webi	alo
to the Active Toxic Class Method (	JECD Guide	11176 423 Novatel Was used as vening	
A dose of 2000 mg/kg body weigh	was grerate	to by male and remaie rats withou	t mortalities, clinical
signs, effects on body weight dev	elopment, a	ad gross pathological findings.	nus, an $LD_{50}$ cut-off
value of 5000 mg/kg by is assign	ed according	to annex a of OECD Guidelin	e 423. Based on this
result, FEA +@FLC, WG /F.II is	not classifie	agor acute oral toxicity accordi	ng to the criteria of
Regulation 12/2/2008.			
	MALASKI	ALS AND METHODS	
A. MATERIALS		ry" Y	
1. Test materi <b>s</b>			
Nome: A A A		WC71 A1 EVD11074D (EEA)	+ ELC WC 71 11)
Description of A	E FUSSOIO U	0 WG/TAT - EAPTIO/4D (FEA -	F FLC wG /1.11)
Description. So O' Ala	Burry Delge p		
	F 220200 250/ (***/***) fi	vonicalida	
	5570 (W/W) II 70/ (***/***) £		
	5. / %0 (W/W) IC	0.04 0.02 0.0 86-1:1:6-1.1	aites in scale i -1
stability of test compound: E	xpiry date: 20	104-03-20. Stability and homogen	eny in venicle were
	a determined	•	
2. vehicle: D	emineralised	water	

## 3. Test animals

Species:	Rat		
Strain:	Wistar rats - HSdCpb: WU		
	Males: 8 wooks		
Age.	Females: 8 9 weeks	ð	e b
Weight at desing:	Males: 102 105 g	Ĩ,	
weight at dosing.	Females: $161 - 160 g$	-1	
Source:	101 - 109  g	Gormon	
A colimation pariod:	At least 5 days	German	
Diet:	At least 5 days	0.15	
Diet.	\$ 3883.	0.15, aa iibitum	
Water:	lap water, <i>ad libititin</i>		
Housing:	In groups in standard poly	cages wit	h low-ogist wood
	granules bedding		) in the second se
Environmental conditions:			L A co
Temperature:		Q A Q	O' & N
Humidity:			
Air changes:			
Photoperiod:	12-nour artificial ugnting		
		N X X .	Š, U
<b>B. STUDY DESIGN AND M</b>	ETHODS & C		
1. In life dates: 2002-11-13 to	2002-17-27		×
2. Animal assignment and tr	eatment of A m	~ ~ Q	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Dose:	2000 marks have		
Application route:	AOral, gavage		
Application volume	10 ml/kg hw		
Fasting time:	Botore administration 17+1	h O' Ý	
Group size:	* rate for set		
Post-treatment observation	14 stave		
neriod:			
Observations:	Olinical signe mortality bod	0 U	nev
	signs mortancy, bog		psy
ÊŠ Č		, O <sup>7</sup>	
		A	
	A. RESULTS AND DISCU	SSION	
A. MORIALEY			
Table 7.1. 1: Results of the	e acute toxic class test in rats wi	ith FEA + FLC WG 71	.11
Dose Tostico	logical Conset and duration	Onset of death	Mortality
(mg/kg bw) Ofindi	nggs* ¥°of signs		(%)
	Males		
		_	0
	Sector Sector Females	-	
	3 -	-	0
	$LD_{50} = 5000 \text{ mg/kg bw}$ (males and	females)**	
* Number of dead animats/number of	animals with clinical signs/number of	animals tested.	
** According to Annex 2d of OECD	Guideline 423		

O

**B. CLINICAL OBSERVATIONS** There were no clinical signs of toxicity (see Table 7.1.1-1).

## **C. BODY WEIGHT**

There were no effects on body weight.

## **D. NECROPSY**

There were no abnormalities observed at necropsy.

## **III. CONCLUSION**

FEA + FLC WG 71.11 is non-toxic after oral administration. The acute oral LD<sub>50</sub> for both sexes was greater than 2000 mg/kg bw. Thus, FEA + FLC WG %1.11 is not classified for acute oral toxicity according to the criteria of Regulation 1272/2008.

	×.		i V		<b>V</b>
	O'	O`\$\/			.4
Report:	KCP 7.1.2/01	, 2003, M-2	20872-020		
Title:	Study for acute dermal toxi	city in fats Code	e: AE F <u>Q</u> 53616\$	🕅 WĢ7Ĭ A1 🖑	ĺ "Qʻ
	(EXP11074B)		· _ ~ ~		A Contraction of the second se
Report No.:	C036525			Û S	0
Document No.:	M-220872-020 5				)
Guideline(s):	EU (=EEC) 67/548/EEC A	nnex V, Part B	3; OE 🕮: 402	ŬSEPA)(=EPA):	OPPTS
	870.1200 🤟 🧔	S S			
Guideline deviation(s):	none	à sui	Q <sup>*</sup> O	8 %	
GLP/GEP:	ves 🗸 🖇		s." . Q	~ O'	

## **Executive Summary**

An acute dermal toxicity story with AEF053676 06 WG74, A1, - EXP00074B (FEA + FLC WG 71.11) in Wistar ats was conducted as a light test according to OECD, 402. The test item was moistened in water and was administered occlusively to groups of each five male and female rats at the dose of 2000 mg/kg bw. The exposure duration was 24 h after which the application site was cleaned with water and soap. There were no clinical signs of to scity, local skin reactions or mortality observed. The rats were subjected to necropsy at remination and there were no abnormalities detected. Based on this result, FEA + FLC WG 7.11 ionot classified for acore percutaneous toxicity according to the criteria of Regulation 1272/2008.  $\bigcirc$ 

S III	MATERIALS AND METHODS
A. MATERIALS	
1. Test material:	
Name:	XE F053616 06 WGCI A1 - EXP11074B (FEA + FLC WG 71.11)
Description:	Lightly beige powder
Batch / Lot No.:	OP22026@ > >>
Purity:	Á,35% (Ŵw) propicolide
	68.7% (w/w) fosetyl-Al.
Stability of test compounds	Expiry date: 2004-03-20.
2. Vehicles 2	Moistened with water
3. Test animals	
Species: A A	Rat
Strain: O O N	Wistar rats - HsdCpb: WU
Sex: S	Males and females
Age	Males: 9 weeks
<b>.</b>	Females: 12 weeks
Weight at dosing:	Males: 228 – 250 g
-	Females: 203 – 213 g

Source:			Germany	
Acclimatisation period:	At least 5 d	avs	Germany	
Diet <sup>.</sup>	Tit least 5 d	<sup>®</sup> 3883 0 15	ad libitum	
Water	Tan water	ad libitum		
Housing:	In groups	in standard nolvcarh	onate cages with 1	ow-dust
Housing.	granules be	dding		ow-duste wood
Environmental conditions:	Branales ee	aamb	O <sub>x</sub>	
Temperature:	22±2 °C		4	
Humidity:	55±5%	ĈA	k k	
Air changes:	ca. 10 h <sup>-1</sup>	Ţ	<u> </u>	
Photoperiod:	12-hour arti	ificial lighting	,Õ <sup>¥</sup> 4	
-				
<b>B. STUDY DESIGN AND M</b>	<b>AETHODS</b>		Č, Č, Č, Č	Y & ÛY
1. In life dates: 2002-11-13 t	o 2002-11-27			
2. Animal assignment and t	reatment	O U X		
Group size:	5 rats/sex	A , O , O G		
Dose:	2000 mg/kg	bw y y o	A.Or w	
Application route:	Dermal oc	clusive «		
Application area:	Up $t_{0}$ $22.5$	cm <sup>2</sup> ,		Ų <sup>×</sup> io
Exposure duration:	24 h		D D D	
Test substance removal:	The treated	area was cheaned with	soap and water	
Post-treatment observation	4 days			×
period:	j k j	y k a k		<i></i>
Observations:	Clinical Si	gns, docal skin reaction	ons, mortality, body	weight, gross
- W	hecropsy			
	°∭. RESU	LTS AND DISCUSSI		
		O LA S	y V	
A. MORTALOTY			, Q	
There were no mortalities (see	e Taple 7. A2-		Ô	
Table 7	S. S.	ut and the set of	≫ ₩ FFA + FLC WC 7	1 11
Table 24,2-1: Results 014		turineous toxicity test y	IIII FEA + FLC WG /	1.11
Dose To	xicological	Onset and duration	Onset of death	Mortality
	Sesuit ~~~~~	i signs		(%)
				0
			_	0
		remailes		0
			-	0
		00 mg/kg bw (males and	females)	
* I <sup>st</sup> number = number of dead a	nimals, 2 <sup>nd</sup> num	ber number of animals wit	th toxic signs,	
3 <sup>rd</sup> number = wamber of anima	s used			
B. CLINICAL OBSERVAT		T 11 7 1 0 1)		
I nere were no conical signs o	Dioxicity (se	e Table /.1.2-1).		
	MC			
U. LOUAL SKINGKEACTIC	JINO and at the site	of application		
	cu at the site	or apprication.		
<i>u</i> • -				

## **D. BODY WEIGHT**

There were no effects on body weight.

## **E. NECROPSY**

There were no abnormalities observed at necropsy.

in árritatóð n

## **III. CONCLUSION**

FEA + FLC WG 71.11 is non-toxic after dermal administration. The acute percutaneous LD<sub>50</sub> for both sexes was greater than 2000 mg/kg bw. Thus, FEA TLC WG 7271 is not classified for acute percutaneous toxicity according to the criteria of Regulation 1272/2008.

#### **CP 7.1.3** Inhalation

No inhalation test has been conducted with FEA FLQWG II.11. The potential for inhalation exposure to the product as is going to be negligible since both active substances are not volatile and the product is practically dust free ( ; 2003; M£215267-01-1). However, information on this endpoint is required for all products applied by spraying. For animal welfare reasons, a new inhalation study is not deeped reasonable. Instead, the inhalation toxicity is predicted using the provisions of Regulation 1272/2008 Annex P. Section 3.13.6.2 To this end, the available inhalation toxicity information is compiled for all components of PEA +FLC WG 71.11, in the respective CONFIDENTIAL part (Document JCP). In conclusion, FEA + FLC, WG 71.11 is predicted to be nonetoxic of inhaled. The acute toxicity estimate for FEA + FLC WG 71 H is 99 mg/ Thus FEA FLC WG J9.11 is not classified for

acute inhalation toxicity according to the criter of Regulation 1272/2008

**CP 7.1.4** 

2002; NA-223952-01-1 **Report:** CP7.1.4/0 Acute dermal irritation in tabbits Gode: APF053646 06 WG71 A1 (EXP11074B) Title: Report No.; 🖗 £037987 Ô OM-223932-0 Document No.: Guideline(s): Guideline deviation **GLP/GEP:** 

## Executive Summary

A primary dermal irritation / corrosion study in Now Zealand White Rabbits was conducted with AE F053676 06 WG71A1 (FEX + Floc WG 1.11) According to OECD guideline 404.

A quantity of 0.5 g the test item was applied to convoistened cotton patch of size approximately 6 cm<sup>2</sup> and applied on to the prepared area of the skin After 4 hours, the treated area was wiped off with a moistened cotton pad.

The degree of initiation was scored at 1, 24, 48 and 72 hours after removal of the test patch. Except for a very slight crythema (grade 1) noted in one animal one hour after removal of the dressing, no cutaneous reactions were recorded during the study. Mean scores over 24, 48 and 72 hours for each animal were 0.020.0 and 0.0 for erythema and oedema. Based on this result, FEA + FLC WG 71.11 is not classified for printary skip irritation according to the criteria of Regulation 1272/2008.

### I. **MATERIALS AND METHODS**



				Scoring t	ime (h)		0	
Rabbit No.		1		24		48	72 🖉 👌	
	E*	0*	Е	0	Е	0	E NO	
1	0	0	0	0	0	) D	0 0	
2	0	0	0	0	0	\$ 0	0~	
3	1	0	0	0	0 🖌	0		
* E: erythema O: oeder	19				\$1	V		

#### Table 7.1.4- 1: **Results of the skin irritation test with FEA + FLC WG 71.11**

E: erythema, O: oedema

## **III. CONCLUSION**

FLCWG 70 11 is not classified for lation 1272/2008 FEA + FLC WG 71.11 is not irritating to rabbit skin. Thus, FEA primary skin irritation/ corrosivity according to the criteria of Regulation 1272/2008

CP 7.1.5	Eye irritation
	•

KCP 7.1.5/01 Acute eye innuation in tabbits Code: AE F05 9616 96 WG71 A1 (EXP11074E C037993 M-223965-01-1 EU (=EEC): 92/69/EEC, B.5; 0ECD: 405 none **Report:** Title: Report No .: Document No.: Guideline(s): Guideline deviation(s): yes **GLP/GEP:** 

## Executive Summary 🖑

An acute eye irritation / corrosion study in New Zealand White rabbits was conducted with AE F053616 06 WG71 AV (EXP 11074B, FEA + FIG WG 1.11), according to the 2002 version of OECD 405. On test day only a quantity of 100 mg of the test item was instilled into the left conjunctival sa?. The right over renained intreated. All the rabbits were treated in a similar manner. The treated eyes were not rinsed.

There was conjunctival redness (maximum score: 3), chemosis (maximum score: 3), and corneal opacity (maximum score: 2) of all rabbits. Two rabbits also displayed iritis (maximum score: 1). All eye reactions had completely reversed by Day 10 after exposure at the latest.

In two animals, the mean scores for conjunctival and cornea effects observed between 24 and 72 h exceeded the threshold values for classification as eye initiant in Category 2 (H319 – Causes serious eye irritation) but did not reach or exceed the threshold for classification as severe eye irritant.

Based on these results, FER + FDC WGO 1.110s classified as Eye Irrit. 2 (H319 – Causes serious eye irritation) according to the criteria of Regulation 1272/2008.

Į.	
~	A.I. MATERIALS AND METHODS
λų°.	
A. MATERIA	S & Q &
1. Test materia	
Name:	🛫 🔊 🔉 🕹 F053616 06 WG71 A1 - EXP11074B (FEA + FLC WG 71.11)
Description:	Granulous beige powder
Batch Lot	D.: A OP220266
Putoty:	4.35% (w/w) fluopicolide
	68.7% (w/w) fosetyl-Al.
Stabil by of tes	t compound: Expiry date: 2004-03-20.
$\bigcirc$	



D.11.4		Conjunctiva		T		
No.	Scoring time	Redness (0-3)	Chemosis (0-4)	(0-2)	(0-4)	
	1 h	2	1	0 🏷		
	24 h	2	2	1		
	48 h	1	1	A		
1	72 h	1	1			
	Day 5	0	₩.	<b>0</b>		
	Mean score 24, 48, 72 h	1.3	1.3	0.3 Č		
	1 h	2				
	24 h	3 🌾	3			
	48 h	3 0			£ 3 °	
	72 h	3	TO SU Q		O' 2' V	
	Day 5	2 🦨 🦿	$\gamma^{\prime} \gamma^{\prime} \gamma^{\prime$			
2	Day 6	Q. IS				
2	Day 7					
	Day 8				° 🌱 0	
	Day 9				× 0	
	Day 10		~ & <sup>~</sup>		0	
	Mean score 24, 48, 72 h	3.02	× 5 3.0 ° 4	L. J.10	2.0	
	1 1		27 0		0	
	24 h 🔍	<u> </u>	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	<u> </u>	1	
	~48 h \		<u>్ల్లో 2</u> నే	e <sup>y</sup> ~90	2	
				0	1	
Ğ	🔋 Day 5	Q 1_		× 0	0	
3	Day 6				0	
	Day 🖗 🗞			0	0	
	Day 8 🔧			0	0	
	Day 95			0	0	
	Day 90° (			0	0	
	Mean score 24, 48, 72 h		2.0	0.0	1.3	
			<b>O</b> NCLUSION			
EA + FLC	W & 71.11 is ir	ritating to rabbit e	yes. Thus, FEA +	FLC WG 71.11 is	classified as Eye	
rit. 2 (H31	9 Causes series	is eye writation) ac	cording to the crite	eria of Regulation	1272/2008.	
,						
		, O				
, so i		<b>V</b>				
E S						
Ű "Ô <sup>v</sup>						
$\bigcirc$						

.

Document MCP – Section 7: Toxicological studies Fosetyl-aluminium + Fluopicolide WG 71.11

## CP 7.1.6 Skin sensitization

Report:	KCP 7.1.6/01 ; 2003	; M-223976-01-1	
Title:	Skin sensitization test in guinea	pigs (Modified Buehler tes	t: 2 applications) ( ale: AE
	F053616 06 WG71 A1 (EXP110	(74B)	
Report No.:	C037998		
Document No.:	M-223976-01-1	4	
Guideline(s):	EU (=EEC): 96/54/EEC, B.6; OI	ECD; 406	
Guideline deviation(s):	The Buehler test was conducted	in a modified version using	9 instead of 3 inductions
GLP/GEP:	yes	. °	

## **Executive Summary**

The potential of the test item AE F053616 06 WG71 A1 (EXP 11074B; FEA + REC WG 71.1. 1) to induce delayed contact hypersensitivity following cutaneous application was evaluated in guinea pigs according to the modified Buehler method. Ø n Thirty guinea pigs (15 males and 15 females) were allocated two groups: a control group (five males and five females) and a treated group (ten males and ten females).  $\bigcirc$ During a 3-week induction period, the animals of the treated group received nine topical applications of the test item. The application sites were covered by an occursive dressing for Chours on each occasion. The animals of the control group received applications of purified water under the same experimental conditions. On day 29, after a rest period of g days, animals of both groups were challenged by a topical application of the test item to the right flagk. Purified water was applied to the left flank under the same experimental conditions. Test item and ourified water were maintained under an occlusive dressing for 6 hours. Skin reactions were evaluated approximatel 24 and 48 hours after removal of the pads. Test item concentrations were as follows Induction 50% (w/w) on dors 1, 2, 5, 8, 10, 12, 15, 17 and 19. Challenge: 25% ( w) on day 29. The vehicle used was publied water. No clinical sign and of deaths related to treatment were noted during the study. During the induction period no well-defined skip reactions were observed. After the challenge application at the 24-hou reading, a discrete ovthema was noted in 4/10 animals of the control group and in \$20 animals of the treated group. At the 48-hour reading, a discrete erythema persisted on the right treated flank of 140 animals of the control group and appeared on the left control flank of 1/20 animals of the treated group to other erythema was noted. No cutaneous reactions attributed 1:0 delayed contact hypersensitivity were recorded during the study. A contemporary reliability preck using 2 mercarobenzothiazole showed a high rate of sensitization demonstrating the refrabilito of the test system. Based on this result, FEA<sup>4</sup> FLOWG JF.11, is not classified as skin sensitizer according to the criteria of Regulation 1272/2008 MQTERCALS AND METHODS A. MATERI 1. Test material ÀAE F053616 06 WG71 A1 - EXP11074B (FEA + FLC WG 71.11) Name: Granulous beige powder Description Batch / Lot No. OP220266 Parity: 4.35% (w/w) fluopicolide 68.7% (w/w) fosetyl-Al. Stability of test compound: Expiry date: 2004-03-20.

2. Vehicle:	Purified water
3. Test animals	
Species:	Guinea pigs $Q^{\circ}$
Strain:	Hartley Crl: (HA) BR
Sex:	Males + females
Age at first induction:	1-2 months
Weight at first induction:	Males: $346 \pm 18$ g
	Females: $346 \pm 11$ g
Source:	, France. 🖉 🔗
Acclimatisation period:	At least 5 days
Diet:	106 pelleted diet (, France)., &
	ad libitum
Water:	Drinking water phered by a 0.52-µm vaembrane, an <i>Holtum</i>
Housing:	27 cm x 20 m 2 x x x x x x x x x x x x x x x x x x
Environmental conditions:	
Temperature	$22\pm2$ °C $2$ $2$ $2$ $2$ $2$ $2$ $2$ $2$ $2$ $2$
Humidity:	30-70%
Air changes:	approx. 12h <sup>M</sup> a a a a a a a
Photoperiod:	129 light@12 h dark 🗸 🚿 🖓 🖉
<b>B. STUDY DESIGN AND M</b>	THODS OF A A A
<b>1. In life dates:</b> 2002-10-21 <sup>st</sup> to 2	2002-11-20 4 6 4 2
2. Animal assignment and trea	atment a star star star star star star star s
Group size:	Pre-study: 27 //sex for induction: 4 (2/sex) for shallenge
	Control: $a.10 (5/\text{sex}) < 10^{-3}$
	Test item: 20 (10/sex)
Induction:	
Expo@re ro@e:	Epiçutane ous, occlusive
Schedule: 👸 💞	Days 1, 3, 5, 8, 40, 12, 5, 17 and 19
Concentrations	50% (₩ W) 0 <sup>-1</sup> 0 <sup>0</sup> 0 0 <sup>-1</sup>
Application site:	Anterior left flank
* Exposure duration	
Exposure route	Enjoyténeorte ecclusive
Schedule:	Dat 29 2 2
Concentrations:	$25\%$ ( $\sqrt{3}$ ) $\sqrt{3}$
Application site?	Posterior right flank
Dixposure duration: 🖉	$6 h \mathbb{Q}^{r} \overset{\sim}{\sim} \overset{\sim}{\sim} \overset{\sim}{\sim}$
Scoring times:	24 and 48 h after and of challenge exposure
Scoring system:	Magnusson-Kugman scale as laid down in OECD 406
Negative controls:	Negative controls received sham inductions with vehicle (water) but
	wete challenged with the test substance as described above.
Reliabilitycheck	Positive control: 2-mercaptobenzothiazole (20% w/w for induction
	and chanlenge), conducted in October 2002
$c_{l}^{O^{v}}$	
$\checkmark$	

## **II. RESULTS AND DISCUSSION**

## A. MORTALITY

There were no mortalities.

## **B. CLINICAL OBSERVATIONS**

**D. CLIFFICAL OBSERVATIONS**Hypoactivity and dyspnoea were observed in 1/10 animals of the control group between day 19 and day 22. No other clinical signs were observed during the study. **C. BODY WEIGHT**There were no effects on body weight. **C. SKIN REACTIONS**During the induction period no well defined also protective.

During the induction period, no well-defined skinffreactions were observed. After the challenge application, at the 24-hour reading a diserved grythema was noted in 4/10 animals of the control group and in 4/20 animals of the treated group (see Table 7.106-1). (At the 48-hour reading, a discrete erythema persisted on the right treated flank of 1/10 animals of the control group and appeared on the left control flank of 1/20 animals of the treated group, no other erytheme was noted.

No cutaneous reactions attributed to delayed contact hypersensitivity were received during the study.

## Table 7.1.6- 1: Results of the Buehler test with EFA + FSC

	Antonal	<b>Day 30 (a</b>	fter 24 hours) 🔗	Day 31 (after	e48 hours)
Sex	Animai	Left flank∕	<b>P</b> Right flank@test	Left flank	<b>Right flank</b>
	number	🔪 (vehicle) 🛛 🖉	j 🖉 item) 🔍	🗸 (vehicte) 🖉	(test item)
Control g	oup			&	
Male	51			O* \$\$0/S *	0/S
	52	0 🖇 🛓			0/S
	53 🔊		) <sup>y</sup> ~ .00 ~ ~		0
	540	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		NO NO	0
	55				1
Female	66			K 0	0
	67	× × ×			0
Į.	≥° 68			$\bigcirc_{\lambda} = 0$	0
**	69			✓ 0/S	0
	70 🝣			0/S	0/S
Treated g	roup 👸				
Male	56			0	0
	~\$7 (			0/S	0/S
	<u> </u>	Or QO A		0/S	0/S
	»" 59			0	0
	60			0	0
<i>k</i>	61 🔬			0/S	0
- *	62	Or Er ~	≪ O <sup>× 1</sup>	0	0/8
	6.5 ×			0	0
				1	0
	600 J			0	0
(		ర స్	5		
<u> </u>	, D				
Á					
L' <sup>S'</sup>	Ğ '0'				
	S.				
Ĉĭ					

Document MCP – Section 7: Toxicological studies
Fosetyl-aluminium + Fluopicolide WG 71.11

	Animal	Day 30 (after 24 hours)		Day 31 (afte	er 48 hours)
Sex	Aiiiiiai	Left flank	Right flank (test	Left flank	Right flank
	number	(vehicle)	item)	(vehicle)	(test item)° 🚕
Female	71	0	0	0	0.0
	72	0	0	0	A O
	73	0	1	0 🖉	ão d
	74	0	0	0	× 0, ×
	75	0	0	04	
	76	0	0		
	77	0	0 🖏	- sγõ	
	78	0	0 🔊		
	79	0	1 🛴	, Õ <sup>♥</sup> 0/S 📣	0, °°, 0, °°, 0'
	80	0	<i>₽</i> ₽ <sup>×</sup>		
S : dryne	ss of the ski	n			

# III. CONCLUSION

ienot FEA + FLC WG 71.11 is not skin sensitizing in the Buenler test. Thus, FEA+ classified as skin sensitizer according to the criteria of Regulation 1272/2008. C AND C AND

## **CP 7.1.7**

Supplementary studies on the plant protection product necessary once there are no concerns arising e.g., from the plant of the substances of other complete inter investigations. No such studies are necessary gince there arono concerns arising e.g., from potential synergistic or additive effects exerted by the active substances or other components on the plant protection product that would require further investigations.

## Supplementary studies for combinations of plant protection products **CP 7.1.8**

CP 7.1.3 Suplementary studies for combinations of plant perfection products.

### **CP 7.2** Data on exposure

Evaluations of the exposure of operators, bystanders, residents and re-entry workers to foselylaluminium (fosetyl-Al) when used in Fosetyl-Al + Fluopicolide WG 71.11 (FEA + FLC WG 1.11) formulation are provided in the following sections.

### **CP 7.2.1 Operator exposure**

FEA + FLC WG 71.11 is a water dispersible granule containing 666.7 g/kg fosetyl-M and 44 fluopicolide. The proposed representative use is as a fungicide on grages. Applications of SEA + DLC WG 71.11 will be achieved via broadcast air assisted sprayers. Water will be the diluenocarries in alk situations. The full representative GAP information is given in Councert Diand is summarised in Table 7.2.1-1.

		× 1	Ŋ	~
Table 7.2.1- 1:	Application parameters	for <b>BEA</b>	+ PLC	WG 71.1
			,	

		. //	A . 0		<i>Y</i> 4		0.	, é
Application	Crop(s)	Growth	Maximun	n dose rate	Spray 🦻	Max 🖉	🦉 Spray	Pari
technique		stage or			, Polume	N° 🔗	Interval	(day)
		G	kg/ha	kg/ha	(L/har)	treat-	aday) Q	)
		\$' b	product	fosety	0	ments		
BAA	Grapes	Ø5-81 ₩F	<b>©</b> 3	,¢	0 <sup>9</sup> 100- 0	3	1@-14	21
					1000	ŝ	0'	

BAA = Broadcast air assisted sprayers F = Field use, G = Greenholdse

Dermal absorption:

The following dermal absorption values for fosetyl A are used in the present risk assessment (for details see Section CP A): details see Section CP (3):

• 7% for the concentrate (measured at 666.7 g/s) and 4% (measured at 2 g/L with a predicted lowest in-use concentration of 2 g/L) for the spray dilution.

Acceptable Operator Exposure L evel AOE

An AOEL of 5 mg/kg bw/day is established for fosetyl All based on the NOAEL of 500 mg/kg bw/day obtained in a 96-day mechanistic rat study using a safety factor of 100 with no adjustment for



<sup>1</sup> Fosetyl, EFSA Scientific Report (2005) 54, 1-79, Conclusion of the peer review.

## Operator exposure estimates

Operator exposures to FEA + FLC WG 71.11 are estimated using the German model<sup>2</sup>, the UK-POEM<sup>3</sup> and the new EFSA calculator<sup>4</sup> (although not implemented at the time of writing) with the relevant scenario "Tractor-mounted/trailed broadcast air assisted sprayer". Details are given in Section CP & 7.2.1.1 and in Table 7.2.1.1-1 to Table 7.2.1.1-3. 

The results of the exposure calculations are summariz	zed	in	Table	7.3	2.1	- 2
The results of the exposure euleulations are summarized	Jou	111	1 4010	1	<b>.</b>	



Substance	PPE	Total systemic exposure	% of AOEA	
		(mg/kg bw/day)*		) O
	Geri	man model 🤍 🥠	Q, Or &	Ő
Tractor-mounted/tr	ailed broadcast a	ir assisted spravor: hydraulic ne	gzles. Sha 🞺	Š
Eccetul A1	No PPE <sup>1</sup> O	Q \$11566 2	€ <sup>2</sup> 2, A	
rosetyi-Ai	With PPT, 2)	© 0.02775	S 0.6 S'	Ĩ
	Á Ú	K-POEM		S.
Tractor-mounted/tra	uiled broadcast ai	r assisted sprayer: hydraulie no	zzle <b>A5 ha</b> S	)
Focotul A1	No PP	× × 1.762588 ~	S 5 4	
rosetyi-Ai	With PPE 4)			
Ţ,	°∼ _ĘFSA	Calculatory	Or NY	
Tractor-mounted/tra	uked broadaast aj	r assisted sprayer. hydraulic no	zzles, 10 ha	
Eccetul Al	No PPE 5)	لَيْ 0. <b>168</b> 0997∜ يَ	3	
	Wath PPE	0,0483234 K		
# Equated Alt	ma huddall		A.	

2) Gloves during mixin Doading and a standard cover all during application.

3) One layer of typical work wear (e.g. trousers and a long sceved shirt) as well as sturdat boot wear

4) In addition to typical work wear (sec) protective gloves are with during article state of the , G surfaces Ŵ Ľ

surfaces. 5) Pogential exposure without RPE@PE.

loves are worn during natific and loading and when handling contaminated 6) In addition to typical work wear (see surfaces.

Q.

Å

## **Overall assessment**

Exposure estimates predict no unacceptable risk. Operators using FEA+FLC WG 71.11 for the representative use on grapes should wear odequate work clothing (e.g. a long sleeved shirt, trousers and sturdy foot weary. All Oree models predict that the product is safe to use without additional PPE. However, the notifier recommends that they also wear protective gloves as a good farming practice during mixing/loading and when handling contaminated surfaces.



<sup>2</sup> 

(1992) Winform Principles for Safeguarding the Health of Applicators of Plant Protection Products (Uniform Principles of Operator Protections); Mitteilungen aus der Biologischen Bundesanstalt für Land- und Forstwirtschaft, Berlin-Dahlem, no 277, 1 - 112 (1992).

Scientific Subcommittee on Pesticides and British Agrochemicals Joint Medical Panel., Estimation of Exposite and Absorption of Pesticides by Spray Operators (UK MAFF) 1986 and the Predictive Operator Exposure Model (POEM) – A User's Guide (UK MAFF); 1992, revised model 2007.

EFSA (European Food Safety Authority), 2014. Guidance on the assessment of exposure of operators, workers, residents and bystanders in risk assessment for plant protection products. EFSA Journal 2014;12(10):3874, 55 pp., doi:10.2903/j.efsa.2014.3874.: Version 30/03/2015.

### **CP 7.2.1.1 Estimation of operator exposure**

Operator exposure to fosetyl-Al in the FEA + FLC WG 71.11 formulation is estimated using the German Model, as well as the UK-POEM and the soon to be implemented EFSA calculator for a tractor mounted/trailed broadcast site tractor-mounted/trailed broadcast air assisted sprayer.

In the following paragraphs the assumptions used for the calculations are summarised.

cthate we were during mixing/loading and w German Model Treated area: Max. dose rate: - FEA: Body weight: **UK-POEM** Treated area: Max. dose rate: - FEA: Min. spray volume: Work duration: o for the concentrate and 4% for the in-use dilution. Body weight:

# Table 7.2.1.1-1: Predicted systemic exposure to fosetyl-Al according to the German model/no PPE and with PPE

Operator exposure esti	mate: German mo	del. Tractor-moun	ted/trailed broadc	ast air-assisted s	sprayer	<u> </u>	ð
Product:	FEA+FLC	C WG 71.11		_			Ş
Active substance:	FEA		a.s. concentration	: 667	[g/l or kg]	6	0*
Formulation:	WG	PPE	during mix/loading	: Respiration:	None	Ű Ó	
Dose [l or kg/ha]:	3.0			Hands:	Glayes	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
Work rate [ha/day]:	8	PPI	E during application	: Respiration:	None		Č0
Body weight [kg]:	70			Hands: 💦	None 🔬		) 1
Inhalation absorption [%]	100		Ĉ	Head:	None 🔬		@-
Dermal absorption [%]	1.0	(concentrate)	- The second sec	Body:	Standard protective	e correrall	s.
	4.0	(dilution)	al a	Ő	× /		, 0 <sup>×</sup>
Colordation of worth our			JU <sup>Y</sup>		· ~ ~ ^	¥ <sub>6</sub> 0' ,®	×.
Calculation of route exp	Spacific composition	a a handlad	- Ectimat	ad Smagura [Path	a huv/d&l O		
Route	[mg/kg a.s.]	[kg/day]	No PPE	Reduction facto	r @ with PRE &		
	0.000	0			O Bringel	I = Inhalation	
IM =	0.008	16.0008	×0.001829		× 0.001829	D = Det mal	
$D_{M(H)} =$	2.0	16.0008	0.45 <sup>2</sup>	♥0.01	2 \$0.00457 <del>2</del>	Mc Mix/Loadhrig	
IA =	0.018	16.0008	0.004/114		0.0640114	A = Application	
$D_{A(C)} =$	1.2		y 0.2943 ~		0294299	°H = Ha∰sĩ	
$D_{A(H)} =$	0.7		Q.16 ~~~	01.0	0:16000	C = Head	
$D_{A(B)} =$	9.6	16.0008	∞ 2.1944	0.05		B=Body	
				Š L		$\sim$	
Absorbed dose:			× ~ ×	PPF Q		PPF	
Absorbed dose.		1	(Estimated	Systemic 9	/Æstimated	Systemic	
Route	- Ro	Absorption[%]	white exposure	evnorune	Soute exposure	exposure	
Route	× .	Grosorpage [70]	[mg/k@bw/day]	mg/kg bw/davl	[mg/kgbw/day]	[mg/kg bw/day]	
				«.	[ing at any any	[mg/kg/0///du/j]	
Dermal <sup>.</sup>	MixBoading	× 10	457166	<sup>6</sup> 00 004579	0 004572	0.000046	
Domai.	Application	S .	2 628703	0 105148	0 544027	0.021761	
Inhalation:	Mix/Loaching SA	400 A	0 0 1829	0 101829	0.001829	0.001829	
Ô	Application		0004114	A 004114	0 004114	0.004114	
		Total =		0.115663	, 0.001111	0.02775	
0*	R V			<u>o</u>			
, Ôj	J. 4	9 A 8	7 0	7, <i>R</i>			
	õ nõ			$\sim$			
K, Y	. Ű Ő		. O <sup>×</sup> √√				
<i>•</i>		× ô		Å,			
			ÿ O' 🔬	<			
Ŷ				)ř			
Q1		ι Ο O	Ö Ö				
~Q~	Ŭ O .						
.1	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	o PA C					
	in a a a a a a a a a a a a a a a a a a a		<ul> <li>.≪</li> </ul>				
R.			~~~~~				
*	N A						
A A		y Q a	Ş				
, ,	<i>'0'</i> C		)				
S.		$\sim Q^{\prime}$					
Ő		W a, <sup>v</sup>					
£ 4	J & 4	. ~ Ő					
A S	' 0' N	, Y					
× 67							
	d in the second						
K A	S.						
»O <sup>v</sup>							
$\bigcirc$							

# Table 7.2.1.1- 2: Predicted systemic exposure to fosetyl-Al according to the UK POEM/no PPE and with PPE



# Table 7.2.1.1- 3: Predicted systemic exposure to fosetyl-Al according to the EFSA Calculator/no PPE and with PPE

		Ехро	sure assessment		
Substance	Fosetyl-Al	Formulation = Wettable granules, soluble granules	Application rate-2 kg a.s. /ha	Spray dilution = 20	Vapour pressure low volatite substances having a
Scenario	Grapes / Outdoor / U	Jpward spraying / Vehicle-mounted	Ğ	Buffer = 5	vapour oressure of Numer applications =3, application interval = 10 days
Percentage	Dermal for product	Dermal for in use diluation = 4	Oral = 100	Inhalation = 100	
Absoprtion	= 1			Ň "	
RVNAS	5 mg/kg bw/day		RVA	kg bw/day	
DFR	3 μg a.s./cm2 per kg a.s./ha			90 daysing of	
Operator Model		Mixing, loading and applicatio	ADEM Q A		
Potential exposure	Longer term systemic	: exposure mg/kg bw/day O	0,169	of RVACO	3,66%
	Acute systemic expos	sure mg/kg bw/day	° 0.9131	% of VAAS	
Mixing and Loa	ading	Gloves = No	Clothing Work wear - arms, body and legs covered	RPS / None's	Soluple bags = 100
Application		Gloves = No	Clething - Work wear - arms, body and legs covered		Grosed cation = No
Exposure	Longer term systemic	exposure@g/kg bw/%ay	0.0505	of RVNAQ	1@1%
(including PPE			"0" ~~ (0		0 <sup>×</sup>
options above)	Acute systemic expos	sure mg/kg bw/@ay	20,2244 ×	% OPRVAAS	<u> </u>
	s	\$ 0 \$			<u>,</u>

## CP 7.2.1.2 Measurement of operator exposure

Not required as assessments demonstrated a safe use using the accepted models.

## CP 7.2.2 Bystander and resident exposure

No EU-wide validated and accepted/implemented official model is currently available for estimation of bystander and residential exposures and the second sec

An approach is presented in this document that considers both dermal exposure – derived from available drift data – and inhabition exposure – derived from an operator exposure model simulating a bystander who is exposed in a similar way, as an improtected operator spraying in the field. Additionally, exposure to esidents is assessed as well

This approach is following a goidance of the German Federal Institute for Risk Assessment (BfR)<sup>5</sup> and is in line with what has been published by US EPA and UK CRD recently. All technical details with regard to figures and assupptions are provided in this guidance.

At the request of the RMS resident exposure using the new EFSA calculator is also presented in this chapter.

5

; Guidance for Exposure and Risk Evaluation for Bystanders and Residents exposed to Plant Protection Products during and after Application, Journal für Verbraucherschutz und Lebensmittelsicherheit Journal of Consumer Protection and Food Safety (2008, in preparation).

No acute non-dietary risk assessment is included in this submission. Lack of scientific guidance or methodology is an acceptable reason for waiving according to Guidance of the European Commission<sup>6</sup>. The absence of such guidance on derivation of an appropriate reference dose ("AAOEL") was recognized by

- the European Food Safety Authority<sup>7</sup>, and
- the European Commission Standing Committee<sup>8</sup>.

Therefore, this waiver is presented in line with the Guidance of the European Commission

Ĉ However as the residential estimates cover an average exposure over Alonger duration it is likely of the residential calculations adequately cover bystander(safety. Exposure estimates and proportions of the system c AOELs accounted for by the estimates are summarised in the following Table 7.2.2.1 and Table 7.2.2.1 and Table 7.2.2.1 summarised in the following Table 7.2.2-1 and Table 7.2.2-2. Detailed information and calculations are presented in Section CP 7.2.2.1.

Predicted systemic exposures as approportion of the AOPP Table 7.2.2-1: Ø Ø

Substance	Scenand (mg/kg bw/day)	ot AOEL					
	Bystander of high supp appreation fractor bounter	с. у С					
	Bystander: adult	0.331					
	Bystander whild a 0.013993	0.280					
Resident exposure after figh cropp application (tractor-mounted)							
	Nesident: adort 201.0018707 4 kg 201	0.0374					
,	$2^{\circ}$ Resident shild $3^{\circ}$ $3^{\circ}$ 0.0084259 $2^{\circ}$ 5	0.1685					
, <sup>(</sup>							

\* Assumes a 60 ke bystander for a redult and 16.15 kg for a child.

Derma obsorption value of 4% was used. Inhalation absorption was taken as 100% for both compounds.

L 1

2.11

			, - X 🔎		0			
Tabl	e 7.2.2̂⇒∕2́:	Predicted sy	stemic cop	osures as a g	proportion o	f the AOI	EL using the l	EFSA calculator
	Ĩ,					°		
	Substanc		anario C	O ♥ ↓ ↓ ♥ota ↓ ↓ exi ↓ ↓ exi ↓ ↓ y	l systemic posure* sg bw@ay)	(mg/	<mark>AOEL</mark> 'kg bw/day)	<mark>%</mark> of AOEL
	~Q 4	Resident	exposure a	ter high cro	pplication	(tractor-r	nounted)	
	Ĩ	© Reside	mt: adul		.0 <u>561</u>			<mark>1.12</mark>
		$\sim$	V A					

**0.1054** Resident: child osetvl-Al Ò, Assumes a 60 kg bystander for an adult and 10 kg for a child.

Dermal absorption value of 4% was used. Inhalation absorption was taken as 100% for both compounds.

L.	4 1	Ű	
_0 <sup>×</sup> /	A .	S	s a
19 K	1 8	× 4)	
A 8	õ	S	Y
	A	0	
N K	A.		

Guidance Jocument for applicants on preparing dossiers for the approval of a chemical new active substance and for the Renewal of a pproval of a chemical active substance according to Regulation (EU) No 283/2013 and Regulation (EU) No 284/2093. SANCO/10181/2013, May 2013.

- Guidance on the assessment of exposure of operators, workers, residents and bystanders in risk assessment for plant protection products. EFSA Journal 2014;12(10):3874).
- Guidance on the assessment of exposure of operators, workers, residents and bystanders in risk assessment for plant protection products. SANTE-10832-2015.

## Assessment

The results of the calculations reveal that the situation with respect to bystander and resident exposure is favourable for the intended use of FEA + FLC WG 71.11.

## **CP 7.2.2.1** Estimation of bystander and resident exposure

29

The following definitions and assumptions for bystanders and residents may be applied.

Bystanders and residents are not involved in application or handling plant protection products or the professional handling of treated crops. The question arises whether it is necessary to distinguish between bystanders and residents in terms of the potential for exposure and health risks. However, of because the circumstances of this exposure could differ with respect to appoint, frequency and duration, this seems to be reasonable.

<u>Bystanders</u> may inadvertently be present within or directly adjacent to advarea for a short period of time, typically a matter of minutes, where application of a plant protection product is in progress or has recently taken place. They may be exposed to plant protection products mainly *via* the derival route from spray drift and by inhalation of drifting spray droplets. Hand held application is considered to be worse case compared to field crop sprayer.

<u>Residents</u> may live or work near areas of the application of plant potection products (e.g. standing, working or sitting in a garden in the vicinity of the application). They may be exposed to plant protection products mainly *vic* the dermal route from spray drift deposits and by inhabition of vapour drift (depending on the vapour pressure of the active substance). For infants and toddlers exposure might also occur orally (e.g. through hard to-mouth transfer and/or opject to mouth transfer).

Table 7.2.2.1- 1:	Percent Drift Value	s for Different	t Crops	(Rautmann	et in 2001,	current version
	27,03.2006) - 2 appli	cations. N			4°	

a.V

-Q

~Q

Croit, Distance 10 m Field crops Field crops Fruit crops, early Grapes Grapes Comb Solution Comp Comb Co		
Field crops     0.24       Fruit crops, early     9.61       Fruit crops, late     3.11       Grapes     4.18       Vegetables, ornamentals, essmall/fruit;     0.24       50 cm     0.24	Crop, Distance 10 m	Percent Drift
Field crops     0.24       Fruit crops, eath     9.61       Fruit crops, late     3.11       Oraped     4.18       Vegetables, ornamentals & small truit     0.24       50 cm     0.24       1.07     0.24		2 applications)
Field crops 0 0.24 Fruit crops, each 0 9.61 Fruit crops, late 0 0.24 Orapes 0 0 0.24 Orapes 0 0 0.24 Orapes 0 0.24 Orape		<b>6</b> 2 <sup>nd</sup> percentile values)
Fruit crops, late Fruit crops, late Grapes Hops Vegetables, ornamentals & small/truit: S0 cm 50 sm 1.07 0.24 1.07	Field crops	
Fruit Crops, late Grapes Hops	Fruit crops, early	<u>9.61</u>
Grapes , , , , , , , , , , , , , , , , , , ,	Fruit Crops, 197	3.11
Hops v v v v v v v v v v v v v v v v v v v	Grapes , O' x	, <sup>y</sup> & Å 1.07
Vegetables, ornamentals & small Guit: 50 cm 50 c	Hops Or J O	4.18
$\frac{1}{50}$	Vegetables, ornamentals & small truit:	S S
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.24
	<u>\$ \$50 km ~ 0 ~ 0</u>	1.07

Exposure calculations are performed according to the following equations:

 $\begin{array}{c} \hline \\ Dermal exposure due to spray drift following 2 high crop applications using a tractor mounted field sprayer: \\ \\ SDE_B = (AR x D x BSA x DA) / BW \\ \\ Where: \\ SDE_B = Systemic Exposure of Bystanders via the Dermal Route (mg/kg bw/day). \\ AR = Application Rate (mg/m<sup>2</sup>) \\ D = Drift (%) \\ BSA = Exposed Body Surface A \\ \end{array}$ 4 kg a.s./ha = 400 mg/m<sup>2</sup>. 11.81% (10 m distance) for 2 applications 1 m<sup>2</sup> (adult) 0.21 kp<sup>2</sup> (child). 4% (adult), 16.15 kg (child). 1.01 (10 matistance) for 2 app 1 m<sup>2</sup> (adult) 0.21 to (child). 4% (adult) 16.15 kg (child). BSA = Exposed Body Surface Area  $(m^2)$ = Dermal Absorption (%) DA BW = Body Weight (kg/person) Systemic Exposure of Bystanders via the Inhalation Route (mg/kg by/day).
Specific Inhalation Exposure (mg/kg cs. handled per day)
Application Rate (kg a.s./ha)
Area Treated (ha/day)
Time [Deration] (min)
Inhalation Absorption (%)
Body Weight (kg/person)
Area Treated of Bystanders:
A Child Inhalation exposure due to spray drift  $SIE_B = (I_A * x AR x A x T x IA) / BW$ Where: **SIE**<sub>B</sub>  $I_A*$ (high crop tractor sprayer). AR  $\bigcirc$ <sup>°</sup>8 ha (field crop sprayer). SLEB (mg/kg bw/eay). IA BW

60 kg (adult), 16.15 kg

Total Systemic Exposo

Adults and Children: SER = SDE Ó<sup>S</sup> Ì

Where:

А Т

= Systemic Exposure of Bystanders (mg/kg byoday). SE<sub>B</sub>

Systemic Dermal Exposure of Bystanders(mg/kg bw/day). SDE<sub>B</sub>

SIE<sub>B</sub>

DE<sub>B</sub> = Systemic Dermal Exposure of Bystanders (mg/kg bw/day). IE<sub>B</sub> Systemic Inhalation Exposure of Bystanders (mg/kg bw/day).

Table 7.2.2.1- 2:	Calculations for bystander exposure to fosetyl-al in FEA + FLC WG 71.11
-------------------	---

Adults	Children 🖉 🥎
Bystander of high crop	application (tractor-mounted)
Dermal Exposure	Dermal Exposure
$SDE_B = (AR \times D \times BSA \times DA)/BW$	$SDE_B = (AR x D x BSA x DA)/BW$
$SDE_B = (200 \times 0.1181 \times 1 \times 0.04) / 60$	$SDE_B = (200 \times 0.1181 \times 0.21 \times 0.04) / 16.15$
$SDE_B = 0.015747 \text{ mg/kg/day}$	$SDE_B = 0.012285 \text{ max}/\text{kg/day}$
Inhalation Expsoure SUE $= (L * x AB x A x T x IA)/BW$	Inhalation Exposure
$SIE_{B} = (1_{A}^{2} \times AK \times A \times 1 \times IA)/BW$ $SIE_{B} = (0.018 \times 2 \times 8 \times 0.1667 \times 1.00)/(60)$	$SIE_B = \Phi_A \cdot XAK \cdot XA \cdot 1 \cdot \chi A / B W$ $SIE_T = 0.010345 \times 10^{-2} \times 10^$
$SIE_{B} = 0.00080000 \text{ mg/kg/day}$	$SIE_B = 0.0000812 \text{ mg/kg/day}$
Total Sytemic Exposure	Total Sylemic Exposure
$SE_{B} = SDE_{B} + SIE_{B}$ $= 0.016547 \text{ mo/ko/day} \qquad (a)$	$\sim$ SE <sub>B</sub> = SDE <sub>B</sub> + SUE <sub>B</sub> $\approx$ $\approx$ $\approx$ $\approx$ $\approx$ $\approx$ $\approx$ $\approx$ $\approx$ $\approx$
0.010047 mg kg ddy	
%AOEL = 0.3309	%AOEL =
b) Residential exposure to fosetyl-Al in the FE	CA+FLC WG Z1011 formulation
Dermal exposure via deposits caused by spray di	<u>inti</u> si
$SDE_R = (AR \times D \times TTR \times TC \times H \times DA) \otimes W$	
Where:	
$SDE_R$ = Systemic Exposure of Residents via	a the Dermal Roofe (mg/kg bw/day).
AR = Application Rate (mg/cm <sup>2</sup> ) $\sim$	$\Im$ $\Im$ kg a.s./ha = $\Im$ .04 mg/cm <sup>2</sup> .
$D = Drift (\%) O^{\gamma} (\%) V^{\gamma} (\%) V^{\gamma}$	39.61% (10 the distance) for 2 applications.
TTR = Tup Transferable Residues $(\%)$	$\sqrt{\frac{50\%}{2}}$
TC = $\text{Transfet Coeff Qient (cm2/hotyr)}$	$5^{\circ}$ $9300 \text{ cm}^2/\text{h}$ (adult), 2600 cm <sup>2</sup> /h (child).
H $=$ Exposure Duration (hours)	$\sqrt{\sqrt[3]{2} h}$
DA $\neq$ Dermal Absorption (%)	
BW $\mathcal{A} = Body W \mathcal{A} ght (kg/person)$	$\odot$ 60 kg (adult), 16.15 kg (child).
Inhalation exposure due to vapour drift.	Č Č
$SIE_R = (AC_V \otimes IR \times IA) / BW$	Y 🔬
Where: $\overline{\phi}^{\gamma}$ $\phi$ $\overline{\phi}^{\gamma}$ $\dot{\phi}^{\gamma}$	
$SIE_R $ = Systemic Exposure of Residents via	a the Inhalation Route (mg/kg bw/day).
$AC_V = Airborne Concentration of Vapour$	$pmg/m^3$ ): 0 mg/m <sup>3</sup> (vapour pressure of a.s. < 10 <sup>-5</sup> Pa).
IR = Inhalation Rate $(nr/day)$	$16.57 \text{ m}^3/\text{day}$ (adult), $8.31 \text{ m}^3/\text{day}$ (child).
IA = Invalation Absorption ( $\frac{2}{3}$ )	100%.
BW = Body Weight (eg/person)	60 kg (adult), 16.15 kg (child).
As the vapour pressure of fose y1-Al is $<10^{-7}$ Pa	at 25 °C the product is considered as non-volatile and
therefore $AC_{V} = 0$ and $SIE_{R} < 0$ .	
A A A	

In addition, oral exposure of children is estimated by the following equations: Children's hand-to-mouth transfer:

$$SOE_H = (AR \times D \times TTR \times SE \times SA \times Freq \times H \times OA) / BW$$

 $\begin{aligned} & ... Route (mg/kg bw/day). & 4 kg as./hak = 0.04 mg/cm^2. \\ & 9.61\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 50\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 50\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 50\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 50\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 50\% (10^{\circ} m distance) for 2 applins to 5\%. \\ & ... ractor (%) & 20 fem^2 & 20 fem^2$ Where: **SOE**<sub>H</sub> AR D TTR SE SA Freq Η OA BW Children's object-to-mouth transfer  $SOE_O = (AR \times D \times DFR \times IgR \times OA)^{*}B$ Where: **SOE**<sub>O</sub> AR D DFR IgR OA BW Total systemic exposure of residents Jung Kg bw/day) Jung Kg bw/day). Jung Kg bw/day). Jung Kg bw/day). Systemic Interation Exposure of Residents (mg/kg bw/day). Systemic Oral Exposure via the bland to Mouth Route (mg/kg bw/day). SOE<sub>0</sub> S = Systemic Oral Exposure via the Object to Mouth Route (mg/kg bw/day). SOE<sub>0</sub> S = Systemic Oral Exposure via the Object to Mouth Route (mg/kg bw/day).

Table 7.2.2.1- 3:	Calculations for resident exposure to fosetyl-Al in FEA+FLC WG 71.11.
14010 / 2.2.1 0.	Curculations for resident exposure to rosetyr firm r Erit i Ee () G / 1111

Ad	lults		Children 🖉 🐎			
Resident: Exposure after 2	2 applications v	with Field Crop	, tractor mounted/trailed	broadcast air ass	isted sprayer	
Dermal exposure:			Dermal exposure:	× <sub>(</sub> v <sup>2</sup>	<u></u>	
$SDE_R = (AR \times D \times TT)$	R x TC x H x D	A) / BW	$SDE_R = (AR \times D^{\circ})^T$	TR x TC x H x D	A BW	
(0.04 x 0.0961 x 0.05	x 7300 x 2 x 0.	04) / 60	(0.04 x 0.096 <b>f</b> x 0.05	5 x 2600 ©2 x 0@	¥) / 16.95	
Absorbed dose:	0.00187075	mg/kg bw/d	Absorbed dose:	0.50247539	mg/kg bw/d	
Inhalation exposure:		- A	Inhalation Exposure:			
$SIE_R = (AC_V \times IR)$	x IA) / 1000 x	BW A	Q SIE <sub>R</sub> = (AC	v x IR x IÅ) / BW		
(0 x 16.57	x 100%) / 60			x 100%) / 16015		
Absorbed dose:	0.0	mg/kg bw/dQ	Absorbed dose:	Ů.Ů Ů.Ø	mg/kg bw/d	
		A T	Oral oposure hand-to-	mouto transfor).	Å	
	"ג		$\rightarrow$ SOE = (AR x D x $f$ TR	x SE x SA x Freq	(XH x OA) /	
U & Y V				ABW NO AS	\$ }	
	Ő¥		~~(0.04 × 0.096) × 0.05 ×	0.5 x 20 x 20 x 2	x 1) / 16.15	
	Q, r	., <i>o</i> , (),	Absorbed dose	0.00476037	mg/kg bw/d	
			Gral exposure (Bject-R	mouth transfer):		
	Ĵ,	29 2	SOE₀ ⊊ (AR x ) x	DFR x IgR x OA	.) / BW	
×. (			(0.94 x 0.961 x 0.2 x 25 x 1) / 16.15			
			. O «Absorbed dosed	0.00119009	mg/kg bw/d	
Total systemic exposure:		Q S S	Total systemic exposu	re:		
$\widehat{SE}_{R} = \widehat{SDE}_{R} + \widehat{SIE}_{R} \xrightarrow{4} 2$			$SE_R = SE_R + SIE_R + SOE_H + SOE_O$			
Total absorted dos	0.00187075	@rg/kg by/d	Totakabsorbed dose:	0.00842586	mg/kg bw/d	
% of AO/EL: 3	0.037		% of AOEL:	0.1685		
Resident exposure using t	he EFSA calo	matator: X	A Å			

Ì Bystander and resident exposure to fosety Al during and following the use of the FEA WG 80 formulation is estimated using the EFS ocalculator and the scenario "Upward spraying, Vehicle-Ľ 8<sup>0</sup> mounted". Ò Ì¢ 

Ĩ

C

0

Four pathways of exposure are considered (ELSA PPR Panel, 2010): Ö

- spray drift (at the time of application)
- vapour (may occup after the PPP has been applied)
- surface doposits
- Ontry into treated crops Q, 21 A,

0 75<sup>th</sup> percentiles are considered for the ingle pathways and the total exposure from all pathways is calculated as mean value. A summary of the exposure calculations using the EFSA calculator for the critical GAP (see Table 7.2 (31) is presented below.

#### Table 7.2.2.1- 4: **Resident exposure calculation (using the EFSA calculator)**

Substance	Fosetyl-Al	Formulation = Wetta granules, soluble granules	able Applica 2 kg a.s	tion rate . /ha	Spray dilut 20 g a.s./l	ion =	Vapour pi low volati substance vapour p <5*10-3P	ressure <sup>°=</sup> ile shaving a essure of a
Scenario	Grapes / Out	door / Upward sprayii	ng / Vehicle-n	nounted I	Buffer $= 5$		Nuntper	
			(	Ĉ4	Ľ,	8	Applicatio	$a_{3} = 3, $
			1			Č Q	= 10 days	
Percentage	Dermal for	Dermal for in use	<mark>Orak</mark> ∓ 1	<mark>اي ۱00</mark>	Ahalation =	= 100 <sup>°</sup>	Q,	S W
Absoprtion	$\frac{\text{product} = 1}{2}$	$\frac{\text{dilution}}{4} = 4$		, Q <sup>y</sup>	0		s Č	ĵ <u>o</u>
<b>RVNAS</b>	5 mg/kg		<b>BANAAS</b>	S 🔊 🔪	mg/kg bw/	Qáy 、C	) B	<u>o</u>
	bw/day		×	<u> </u>	N O	<u>~</u> ~		<u> </u>
DFR DFR	$3 \mu g a.s./cm^2$	per kg a.s./ha	<u> </u>	$-\sqrt{2}$	<u>30 days</u>	<u> </u>	<u> </u>	$\sim$
		Å		<u>v</u> v	ð.	107		× af.°
Resident - ch	<mark>nild Spray d</mark>	rift (75th percentile)	ng/kg@w/day		<u>0.1141</u> C	<mark>ې % of</mark>	RVNAS	<mark>2@8%</mark>
	<mark>Vapour</mark>	(75th percentile)(mg/	kg bw/day	<u> </u>	Ç <mark>0.0014</mark>	<mark>%øf</mark>	RVNAS	<b>0.02%</b>
	<b>Surface</b>	deposits (75th percer	tile) mg/kg by	widay 🔬	0, <b>0037</b>	🛛 🧖 of	R NAS (	© <mark>`0.07%</mark>
	<mark>Entry i</mark> 1	nto treated crops (75th	vpercentile) m	g kg bwoday	<mark>ر0327</mark>	S <mark>% of</mark>	<b>KVNAS</b>	<mark>0.65%</mark>
	<mark>All patl</mark>	ways (mean) mg/kg t	<mark>ow/day</mark>		0 <mark>0.1054</mark>	_ <mark>%_0}</mark>	RVNAŠ	<mark>2.11%</mark>
Resident - ad	<mark>lult</mark> Spray d	rift (75th percentale) 1	ng/kg bw/day	D L	0.0623	<mark>% of</mark>	<mark>RVŇAS</mark>	<mark>1.25%</mark>
	Vapour Vapour	(75th percentile) mg/	kg bw/day	L A	0.0002	<mark>Ô% of</mark>	<b>XVNAS</b>	<mark>0.00%</mark>
	Surface	deposits (75th percer	tile) mg/kg by	v/day 炎	° <b>⊳.0007</b> ⊘	<mark>) % of</mark>	<mark>ŘVNAS</mark>	<mark>0.01%</mark>
	Entry i	nto treated crops th	percentile) m	g/kg_bw/daŷ	0.01 <b>82</b>	<mark>% Øf</mark>	<mark>RVNAS</mark>	<mark>0.36%</mark>
	All patl	ways (mean) mg/kg l	w day	A L	0.0561	Store of	<b>RVNAS</b>	<mark>1.12%</mark>
	Ś				&. °			

#### ${\mathbb O}^{\vee}$ s, Measurement of Bystander and resident exposure **CP 7.2.2.2**

Since the exposure estimate carried out indicated that the acceptable operator exposure level (AOEL)



## CP 7.2.3 Worker exposure

The worker re-entry exposure has been calculated for fosetyl-Al following application of the FBA + FLC WG 71.11 formulation for the representative use on grapes. The estimation is provided in the following section.

## **CP 7.2.3.1** Estimation of worker exposure

The greatest potential for worker exposure following re-energy will be contamination via the skin. Risk of inhalation exposure during re-entry is generally confined to a brief period after application, while the product is drying, which will be rapid under outdoor conditions and would generally be avoided according to good agricultural practices. Exposure to workers entering treated areas are predicted using an exposure model proposed by  $table et al.^9$  (4998) and  $table et al.^{10}$  (2001). The following assumptions are made:

- Re-entry exposure is predominantly via the derma rout acontact with the foldinge)

 $\bigcirc$ 

- Residues on the foliage depend on
  - i) application rate
  - ii) extent of remaining residues from previous applications
  - iii) the Leaf Area Index (LAI) total size of soliage compared to surface area]
  - Transfer of residues from foliage to the clothes or skin of workers depends mainly on the intensity of contact with the foliage.
  - Activities with a similar pattern can be grouped and a generic Pransfer Coefficient (TC) applied
  - Dislodgeable Foliar Residue (ØFR) is calculated using a default value of 3 μg as/cm<sup>2</sup> per kg as/ha. This figure is based Brouwer *et al.* (2001)
  - Workers resoluter the treated culture shortly after the spray has dried on plant surfaces, nevertheless it is now recommended to use the higher dermal absorption values amongst neat and diluted values.

The dermal provide calculation is performed according to the following equation: D = DFR OFC x WR x AR x P

Where: DFR = Dislodgeable foliar residues (trg/as/cm<sup>2</sup>) TC = Transfer Coefficient (cm<sup>2</sup>/person/h)

11

- WR = Work rate (hours/day).
- AR @= Apponention Fate (kg as/ha).
- P = Protection factor for PRE (P = ) no PRE, just a long sleeved shirt, or 0.1 when adequate clothing and groves are work).

Ô

<sup>9</sup> growing areas after application of plant protection products; Nachrichtenbl. Deut. Pflanzenschutzd. 50 (10), (1998) 467 - 269).

(2001) Univorm principles for safeguarding the health of workers re-entering crop growing areas after application of plant-protection products, Worker exposure to agrochemicals, chapter 8, 107-117, CRC Press (2001). (2001); Modeling re-entry exposure estimates:

techniques and application rates; Worker exposure to agrochemicals, chapter 9, 119-138, CRC Press (2001).

## DFR values:

A maximum of 3 applications is considered in this risk assessment resulting in an estimated worst case DFR of 9  $\mu$ g as/cm<sup>2</sup> per kg as/ha for the EUROPOEM II assessment whilst a default half-life of 30 days was applied when using the EFSA calculator.

## Transfer Coefficient values:

A TC value of 10100 cm<sup>2</sup>/person/h has been used in this risk assessment. This value was obtained from the Europoem II data for grapes and is also used in the new EFSA calculator.

Predicted exposures are compared with the AOEL fesetyl-Al. Systemic exposure values assume the highest measured dermal absorption value for fosetyl-Al in the DEA + FLC WG 71.11 formulation (4%). A body weight of 60 kg is assumed for the re-entry worker. Exposure estimates based proportions of the systemic AOELs accounted for by the estimates are summarised in the following Table. Detailed calculations are presented on the following pages.

# Table 7.2.3.1-1: Summary of predicted fosetyl-Al worker exposures (no PPE) arising from the use of FEA+FLC WG 71.11 and comparison with the respective AOEL

Active substance	Model Systemic S AQEL S of AQEL exposure* (mg/kg bw/day)	1
EE A	Eussopoen 2 0.9696000 4 4 19	
TLA	~ EFŞA Ø 07833273 16	
*3% dern	nal absorption, 60 kg worker	

## Assessment

The exposure of worker to fosetyl-Al-when entering treated areas is well within acceptable levels following application of FEA + FLCWG 74,11 to grapes.

	S	×)	O	Ş	, Q		Ó	. O	,		
Detailed caloulatio	ns of w	orker	posure	, duri	ng re-er	niry:	Ø.	<i>w</i>			
Furonom II:		. 5	A.		, ô <sup>g</sup>	,	Š.,	Ý			
Europoem II.	S.	£	s de la companya de l	Õ <sup>v</sup>	47	K,	Å				
Product Name:	₽EA+F	EC WS	¥71.11≹	1	Ô	$0^{\prime}$	<b>~</b>				
Active substance?	FEA		, O	°~		<i>•</i>	Q .				
	e O	õ.	°∼y i	~	~°~	0	P.				
DA	= Ĉ	j, č	FR 🖉	X	Å C	X	WR	х	AR	х	Р
<u> </u>	, Q	Âug/	/cm <sup>®</sup>	Î	h²/pers/l	h	hrs/day		kg/ha		
Ď		A.	ĝ,	Ø,	10100	х	8	Х	2	Х	1
D ,		, ja	54400	pg a.	Spers/	day					
"Q"	« ₹	e <sup>g</sup> 1	1454.4 :	mæð	.s./pers/	/day					
O <sup>r</sup>	,∽ <sup>→</sup> = ,	Ű.	24.24	øgg/k	g bw/da	ıy					
(Susing)	4.00	% dem	hal abso	prption	n (highe	st va	lue)				
A RA	A=	~~~~	24.24	x 0.	.0400						
	\$ } *	‴√ ≫ 0.9	69600	mg/k	g bw/da	ıy					
e Q											

## EFSA Calculator:



### **CP 7.3 Dermal absorption**

The dermal penetration through human dermatomed skin of  $[^{14}C]$ -fosetyl-Al in the FLC + FEA  $\bigotimes G$ 71.11 formulation was investigated at three concentrations corresponding to the neat product (666.7 g fosetyl-Al/kg) and to two representative dilutions (20 and 2 g fosetyl-Al/L), respectively.

The mean percentage of fosetyl-Al in the FLC + FEA WG 71.11 formulation that was considered to be potentially absorbable (directly absorbed plus total remaining at dose site) over a period of 24 prours for the neat formulation was 0.05% for the human skin. Applying the new EFSA guidance this value adjusts to 0.1%.

The mean percentage of fosetyl-Al in the FLC + FEA WG 71.11 for foundation that was considered to be potentially absorbable (directly absorbed plus total femaining at obse site) over a period of 24 hours for the intermediate dose rate was 0.88% for human skin. Applying the new ERSA godance this value adjusts to 1%.

The mean percentage of fosetyl-Al in the FLOF FE WG #11 formulation that was considered to be potentially absorbable (directly absorbed plus total remaining a dose site) over a period a 24 hours for the low dose rate was 2.0% for human skin. Applying the new EFSA guidance this value adjusts to Ø1 4%  $\bigcirc$ 

According to the new EFSA guidance<sup>12</sup> there is the provision that when the sampling period is 24 hours (which is the case for this soldy) and over 75% of the total absorption (material in the receptor fluid at the end of the study) occurred within half of the duration (12 hours) of the total sampling period that the absorption will be taken as the sum of receptor flood, receptor chamber washes and the skin sample excluding all tape strips. These criteria were met by the frigh group in this study. There is also the provision that a standard deviation equal to or larger than 23% of the mean of the absorption requires the use of an alternative value or rejection of the study. The guidance prefers the approach of adding the standard deviation to the mean to cover the upper 84th percentitie value of the results. Additionally where an overall recovery of less than 25% occurs, a normalisation procedure is to be used by preference. Albeit that the notifier considers that both the value of 25% for the standard deviation limit and the 95% recovery limit to be too conservative, the application of the guidance results in the following values for [C]-fosetyl-Af in the LC +FEA WG 71.11 formulation:

<sup>&</sup>lt;sup>12</sup> EFSA Panel on Plant Protection Products and their Residues (PPR); Guidance on Dermal Absorption. EFSA

Report: Title: Report No.: Document No.: Guideline(s):	<ul> <li>KCP 7.3/01 (FEA+FLC WG 66.67+4.44): [14C]-Fosetyl-Al - In vitro dermal absorption study using human skin SA 14048</li> <li>M-512858-02-1</li> <li>OECD Guideline for the testing of Chemicals</li> <li>Skin Absorption In Vitro Method Guideline 428 (April 2005).</li> <li>OECD Environmental Health and Safety Publications Series on testing and Assessment N° 28, Guidance Document for the Conduct of Skin Absorption Studies (March 2004).</li> </ul>
	EFSA Panel on Plant Protection Products and their Residues (PPR) Guidance on Dermal Absorption, EFSA Journal 2012: 10(4): 2665
Guideline deviation(s): GLP/GEP:	none yes
Material and methods	
Human skin:	Source: France, France
Tost Motorial.	
Non-radiolabelled:	Batch: 20146000/. 0 4 0 6
Radiolabelled:	Purit $\neq 96.0\%$ (w/w). [ethyl-2-1] fosetyl-Al $\neq 0$
Formulation:	The formulation used in this experiment was the fluopicolide + fosetyl-Al WG 71.11 formulation (specification N° 1/20000/4700) containing fluopicolide (44.4 g/kg) and fosetyl-Al (666.7 g/kg). It was used at three nonimal concentrations of fosetyl-Al: 666.7 g/L with 2 spray dilutions of 20 g/L and 2 g/L
Tost system.	flave through diffusion call system (Example call modified Calles France)
Test system:	A flow through diffusion cell system (Franz's cell modified, Gallas, France) was used to study the absorption of the test substance (exposure area of 1 cm <sup>2</sup> skin). A diffusion cell consister of a conor chamber and a receptor chamber between which the skin was positioned. The receptor fluid was Eagle's medium supplemented with 5% hovine serum albumin and gentamycin (50 mg L) at a pH of 7.4. The receptor chamber was warmed by a constant cuculation of varm water which maintained the receptor fluid at $32 \pm 2^{\circ}$ C (close to the formal skin temperature). The receptor fluid was pumped through the receptor chamber by means of a magnetic bar. Before dose application, the integrity of the skin samples was assessed by measuring the trans epidermal water loss (TEWL) from the stratum corneum. Are vaporimeter probe (Tewameter TM300 <sup>®</sup> System, Courage & Khazaka) was placed securely on the top of the donor chamber and the amount of water diffusing through the skin was measured. Skin samples with a TEWL of greater than 15 g/m <sup>2</sup> h were considered potentially damaged and were not used. These samples were replaced by new skin fragments which were also tested for integrity before use in the study.

**Treatment:** The dose preparation was applied to the split-thickness skin sample with a pipette at the rate of approximately 5 mg/cm<sup>2</sup> for the neat formulation (as a powder) and 10  $\mu$ L/cm<sup>2</sup> for the spray dilutions.. The dose preparations were ° assayed for radioactivity content (by LSC) by using dose checks (surrogate dose) taken before, during and after the dosing process The receptor fluid passing through the receptor chamber was collected in Sampling: glass vials held in a fraction collector. The fraction collector was started after dose application. Samples were then collected hourly for the duration of the experiment (24 hours). At 8 hours post-application, the skin was swabbed with freshly prepared 1% v/v Tween 80 in PBS (phosphate buffer saline) using natural sponge swabs in order to remove and retain the non-absorbed dose, until no radioactivity was detected with a Geiger-Müller monitor At the end of the study (24 hours after application), the treated skin and the skin adjacent to the treatment site (surrounding swabs) were swabbed. Each skin sample was tape-stripped to remove the stratum corneum. This involved the application of Monaderm adhesive tape (Monaderm, Monaco) for 5 seconds . before the tape was carefully removed against the direction of hair growth? This procedure was continued until a Shiny appearance of the epidermis was evident, which indicated that the stratum corneum had been removed. The tape-strips yore collected into scitvillation vials for analysis. The skin surrounding the application site (surrounding kin) was separated from the treated skin. Both surrounding skin and tape-stripped treated skin were retained for analysis. Ň Ő The amounts of radioactivity in the various samples were determined by **Radioassay:** liquid sciptillation counting (LSC). Samples were counted for 10 minutes or for 2 sigma % in an appropriate scipullation cocktail using a Packard 1900 TR counter with on-line computing facilities. Quenching effects were determined using an external standard and spectral quench parameter (tSIE) method Efficiency correlation curves were prepared for each scintillation cocktant and were regularly checked by the use of [14C-n-hexadecane standards. The scoptillation courder was recalibrated when a deviation of greater than 2% was observed when counting quality control standards. The imit of detection was taken to be twice the background values for blank amples in appropriate scotillation cockails.

## **Findings:**

sufficiently soluble in the receptor fluid to avoid any risk of back Fosetyl-Al was demonstrated for be diffusion.

0

Measurements of the homogeneous of the three concentrations of formulation applied indicated that it was acceptable.

The study results are presented in Fable (3-1)

Table 7.3-1: Mean distribution of radioactivity at 24 hours after dose application of [<sup>14</sup>C]-fosetyl-Al in a FLC + FEA WG 71.11 formulation at the nominal rates of 666.7 g/kg, 20 g/L and 2 g/L to human skin samples. 1°M

Results expressed in terms of percentage of applied radioactivity           Distribution of radioactivity           Stim swabs (8h)           Distribution of radioactivity           Stim swabs           Distribution of radioactivity	2 g/L to numan sk	in sampies.						2 8			
Results expressed in terms of percentage of applied radioactivity.           Distribution of radioactivity. (% dose)           Neat formulation: High dose         Dilution: (066.7g/kg)         Dilution: Low dose         Dilution: Low dose           Species         Human (n=4)         Human (r=6)         Human (r=6)         Human (r=6)           Mean         SD         Mean         SD         Mean         SD           Skin swabs (8h)         102.54         6.44         105.32         2.33         96.56         2.71           Skin swabs (24h) <sup>a</sup> 0.07         0.12         0.007         0.01         0.18         0.18           Surface Dose (1st to tape-strips)         0.05         0.002         0.002         0.002         0.02         9.23         0.42           Donor chamber         0.11         0.16         0.01         0.15         9.23         0.42           Stratum corneum <sup>c</sup> 0.03         0.04         0.01         0.15         9.23         0.42           Stratum corneum <sup>c</sup> 0.03         0.04         0.01         0.05         0.01         0.01         0.15         9.23           Stratum corneum <sup>c</sup> 0.03         0.04         0.01         0.01         0.15 <td></td> <td></td> <td><b>c</b></td> <td><i>c r</i></td> <td>1 1</td> <td>,</td> <td></td> <td>Ĩ</td>			<b>c</b>	<i>c r</i>	1 1	,		Ĩ			
Distribution of radioactivity (% dose)           Neat formulation: High dose (666.7g/kg)         Dilution: Intermediate dose (20 g/L)         Dilution: Low dose (2 g/L)           Species         Human (n=4)         Human (n=6)         Herman (n=6)           Mean         SD &         Mean         SD &           Species         Human (n=4)         Human (n=6)         Herman (n=6)           SurrAce COMPARTMENT         Mean         SD &         Mean         SD &           Skin swabs (24h) <sup>a</sup> 0.07         0.12         0.00         6.01         0.18         0.18           Total skin swabs         102.61         5.96         10253         1.33         96.56         2.71           Strins wabs (24h) <sup>a</sup> 0.07         0.12         0.00         6.04         0.06         2.66           Surface Dose (1 <sup>st</sup> two tape-strips)         0.05         0.00         4002         0.002         9.033         2.3         0.42           Donor chamber         0.11         0.16         0.01         6.01         0.15         9.23         0.42           Statum corneum <sup>c</sup> 0.03         0.04         9.007         0.064         0.96         2.00           Stratum corneum <sup>c</sup> 0.03         0	Results express	ed in terms o	f percenta	ge of applie	d radioactivi		n de la companya de l	\$			
Neat formulation: High dose         Dilution: (666.7g/kg)         Dilution: Intermediate dose         Dilution: (20 g/L)         Dilution: (22 g/L)           Species         Human (n=4)         Human (n=6)         Human (n=6)         Human (n=6)           Mean         SD         Mean         SD         Mean         SD           Skin swabs (8h)         102.54         6.04         105.32         6.33         96.55         2.71           Skin swabs (24h) <sup>a</sup> 0.07         0.12         0.07         0.01         0.18         40.18           Total skin swabs         102.61         5.96         105.33         1.33         96.56         2.71           Surface Dose (1 <sup>st</sup> two tape-strips)         0.05         0.002         40002         0.002         9.23         0.42           Donor chamber         0.11         0.36         0.01         0.04         0.06         6.07           Skin b         60.22         0.002         9.004         0.06         6.07         6.98         2.78           Surface Dose (1 <sup>st</sup> two tape-strips)         0.05         0.002         9.007         0.064         2.06         2.00           Skin b         60.02         0.04         9.007         0.064         2.00	Distribution of radioactivity (Bridace)										
Near formulation:         Diffuon:         Diffuon: <thdiffuon:< th="">         Diffuon:         Diffuon:</thdiffuon:<>		Noot form	UISUL		tion.	b uose)					
Dose Levels         (666.7g/kg)         (20 g/L)         (22 g/L)           Species         Human (n=4)         Human (n=6)         Human (n=6)           Mean         SD         Mean         SD         Mean         SD           Skin swabs (8h)         102.54         6.04         105.32         2.33         96.56         2.71           Skin swabs (24h) <sup>a</sup> 0.07         0.12         0.01         0.18         0.18           Total skin swabs         102.61         5.96         105.33         1.133         96.56         2.71           Skin swabs (24h) <sup>a</sup> 0.07         0.12         0.01         0.18         0.18         0.18           Total skin swabs         102.61         5.96         0.105         0.002         0.002         0.002         0.02 <td></td> <td>Neat Iorm</td> <td>diation:</td> <td>Intormos</td> <td></td> <td></td> <td></td> <td><u>_</u>Q</td>		Neat Iorm	diation:	Intormos				<u>_</u> Q			
Dost Levels         (000, 12, 12)         (20 g L 1, 12)         (20 g L 1, 12)           Species         Human (n=4)         Human (n=6)         Human (n=6)         Human (n=6)           Mean         SD         Mean         SD         Mean         SD         Mean         SD           Surface coverance         SURFACE coverance         Gath         105.32         Gath         SD         Mean         SD           Skin swabs (8h)         102.54         Gath         105.32         Gath         96.56         2.71           Skin swabs (24h) <sup>a</sup> 0.07         Q.12         0.01         0.N         Q.18           Total skin swabs         102.61         5.96         105.33         1.33         96.69         2.66           Surface Dose (1 <sup>st</sup> two tape-strips)         0.05         0.002         Q.002         0.002         Q.002         Q.23         0.42           Donor chamber         0.11         Q.16         0.10         0.04         0.06         Q.97           Starbar         0.02         0.03         0.04         0.01         0.05         2.00           Starbar         0.05         0.04         0.02         0.01         0.15         0.23           Total	Dose Levels	(666 7d	uose v/kg)		$\sigma/I$	L04 %()	α doses 🐄	Ĉ.			
Mean         SD         Mean <td>Species</td> <td>Human</td> <td><math>\frac{(n=4)}{(n=4)}</math></td> <td></td> <td><u>g/L</u> n (n=6)</td> <td>Horms</td> <td><math>\frac{g}{10}</math></td> <td>V sO</td>	Species	Human	$\frac{(n=4)}{(n=4)}$		<u>g/L</u> n (n=6)	Horms	$\frac{g}{10}$	V sO			
SURFACE COMPARTMENT         Skin swabs (8h)       102.54       607       105.32       233       96.56       2.71         Skin swabs (24h) <sup>a</sup> 0.07       0.12       0.01       0.14       0.01       0.18         Total skin swabs       102.61       5.96       105533       1.33       96.69       2.66         Surface Dose (1st two tape-strips)       0.05       0.00       0.002       0.002       0.02       0.02         Donor chamber       0.11       0.16       0.10       0.04       0.06       0.97         Total % non-absorbed       1023       5.81       105.4       1.35       96.98       2.78         Skin b       0.02       0.04       9.007       0.064       0.96       2.00         Stratum corneum c       0.03       0.04       9.007       0.064       0.96       2.00         RECEPTOR COMPARTMENT         Receptor fluid (0-24h)       0.03       0.03       0.04       0.02       0.01       1.15       0.23       0.17         Receptor fluid (0-24h)       0.03       0.03       0.02       0.01       1.15       0.26       0.72       0.46         Receptor fluid terminal       n.d	S protes	Mean	SD &	Mean	© <sup>™</sup> SD	Mean		Ű,Ö <sup>Ÿ</sup>			
Skin swabs (8h)       102.54       6.07       105.32       6.33       96.56       2.71         Skin swabs (24h) <sup>a</sup> 0.07       0.12       0.07       0.12       0.07       6.01       0.18       91.8         Total skin swabs       102.61       5.96       10533       1.33       96.89       2.66         Surface Dose (1 <sup>st</sup> two tape-strips)       0.05       0.00       90002       0.002       9.23       0.42         Donor chamber       0.11       0.16       0.00       90002       9.23       0.42         Donor chamber       0.11       0.16       0.00       9002       9.23       0.42         Donor chamber       0.11       0.16       0.00       9002       9.23       0.42         Donor chamber       0.11       0.16       9.007       0.064       9.06       9.78         Skin <sup>b</sup> 0.02       0.04       9.007       0.064       9.96       2.00         Skin <sup>b</sup> 0.02       0.04       9.007       0.064       9.96       2.00         Skin <sup>b</sup> 0.02       0.04       0.02       0.01       1.15       9.23         Mathematic Contractionsetic       0.05       0.04       0.02 <td></td> <td>SURFACE</td> <td>COMPAF</td> <td>RTMENT</td> <td>Y</td> <td>,0</td> <td></td> <td></td>		SURFACE	COMPAF	RTMENT	Y	,0					
Skin swabs (24h) <sup>a</sup> 0.07       0.12       0.07       0.01       0.N       0.18         Total skin swabs       102.61       5.96       10533       1.33       96.89       2.66         Surface Dose (1 <sup>st</sup> two tape-strips)       0.05       0.00       0.002       0.002       0.02       0.02       0.23       0.42         Donor chamber       0.11       0.16       0.10       0.04       0.06       0.07         Total % non-absorbed       102.8       5.81       105.4       1.35       96.98       2.78         Skin b       0.02       0.03       0.04       9.007       0.064       0.96       2.00         Stratum corneum °       0.03       0.94       0.01       0.15       9.23       0.42         Receptor fluid (0-24h)       0.03       0.94       0.01       0.05       0.04       0.92       0.01       1.15       9.23         Receptor fluid (0-24h)       0.03       0.93       0.01       0.01       0.15       9.23       0.01       1.15       0.15       0.15       0.15       0.15       0.15       0.15       0.16       0.01       1.15       0.16       0.16       0.16       0.15       0.17       0.46 <t< td=""><td>Skin swabs (8h)</td><td>102.54</td><td>66QA</td><td>105.32</td><td>\$\$3 A</td><td>∱<sup>9</sup>96.56</td><td>2.71</td><td>Ś</td></t<>	Skin swabs (8h)	102.54	66QA	105.32	\$\$3 A	∱ <sup>9</sup> 96.56	2.71	Ś			
Total skin swabs       102.61       5.96       10533       1.33       96.89       2.66         Surface Dose (1st two tape-strips)       0.05       0.00       0.002       0.002       0.02       0.23       0.42         Donor chamber       0.11       0.16       0.00       0.002       0.002       0.002       0.23       0.42         Total % non-absorbed       102.3       5.81       105.4       1.35       96.98       2.78         Skin b       0.02       0.04       0.064       0.96       2.00         Stratum corneum °       0.03       0.04       0.01       9.01       0.15       0.23         Total % at dose site       0.05       0.04       0.02       0.01       5.01       0.15       0.23         Receptor fluid (0-24h)       4.03       0.03       0.04       0.02       0.01       1.15       0.23         Receptor fluid terminal       n.de       0.03       0.03       0.04       0.02       0.01       1.15       0.26       0.72       0.46         Receptor fluid terminal       n.de       0.03       0.03       0.03       0.04       0.02       0.04       0.03       0.15       0.26       0	Skin swabs (24h) <sup>a</sup>	0.07	Q.12	0.01	<ul><li><a>€0.01</a></li></ul>	♥ 0.N	9.18	Ľ.			
Surface Dose (1st two tape-strips)       0.05       0.007       0.002       0.002       0.023       0.42         Donor chamber       0.11       0.16       0.10       0.04       0.06       0.07         Total % non-absorbed       102.8       5.81       105.4       1.35       96.98       2.78         Skin b       0.02       0.04       9007       0.064       0.96       2.00         Stratum corneum c       0.03       0.04       9007       0.064       0.96       2.00         Stratum corneum c       0.05       0.04       9007       0.064       0.96       2.00         Receptor fluid (0-24h)       0.05       0.04       0.02       0.01       6.01       0.15       0.201         Receptor fluid (0-24h)       0.03       0.09       0.15       0.26       0.72       0.46         Receptor fluid (0-24h)       0.03       0.09       0.01       0.04       0.03       0.01         Receptor fluid (0-24h)       0.03       0.09       0.01       0.04       0.05       0.17         Total % directly absorbed d       0.03       0.09       0.01       0.04       0.15       0.17         Total % directly absorbed d       0.05	Total skin swabs	102.61 候	5.96 @°	105-33	1.33	90089	∞ 2.66√				
Donor chamber       0.11       0.36       0.10       0.04       0.06       0.07       0         Total % non-absorbed       102.8       5.81       105.4       1.35       96.98       2.78         KIN COMPAR /MENT       KIN COMPAR /MENT       Kin b       0.02       0.04       0.01       0.064       0.96       2.00         Skin b       0.02       0.04       0.01       0.01       0.15       0.23         Total % at dose site       0.05       0.04       0.02       0.01       0.15       0.23         Receptor fluid (0-24h)       9.03       0.03       0.03       0.02       0.01       0.15       0.72       0.46         Receptor fluid (0-24h)       9.03       0.03       0.02       0.002       0.006       0.04       0.03       0.15       0.12       0.17         Receptor fluid (0-24h)       9.03       0.03       0.03       0.04       0.01       0.15       0.17       0.46         Receptor fluid terminal       n.d       9.03       0.03       0.86       0.26       0.90       0.51         Total % directly absorbed d       9.03       0.03       0.86       0.26       6.90       0.51         Strupy:	Surface Dose (1 <sup>st</sup> two tape-strips)	0.05	0.0	×0/002	0.002	9.23	0.42				
Total % non-absorbed       102.8       5.81       105.4       1.35       96.98       2.78         Skin b       6.02       0.04       0.07       0.064       0.96       2.00         Stratum corneum c       0.03       0.04       0.01       0.15       0.23         Total % at dose site       0.05       0.04       0.02       0.01       0.01       0.15       0.23         Receptor fluid (0-24h)       0.03       0.09       0.03       0.09       0.01       0.12       0.01         Receptor fluid (0-24h)       0.03       0.03       0.03       0.02       0.002       0.006       0.04       0.03         Receptor fluid (0-24h)       0.03       0.03       0.03       0.02       0.006       0.04       0.03         Receptor fluid terminal       n.d       0.03       0.03       0.03       0.01       0.15       0.17         Receptor chamber       n.d       0.03       0.03       0.04       0.04       0.05       0.17         Total % directly absorbed d       0.03       0.03       0.86       0.26       0.90       0.51         STUDY:       0.05       0.05       0.02       0.88       0.26       2.02       2.4	Donor chamber	0.11	0,16	0.10	0904	0.06	007	Ç			
Skin b       Ø.02       0.04       9.007       0.064       Ø.96       2.00         Stratum corneum c       0.03       0.04       0.01       0.01       0.05       0.04         Stratum corneum c       0.05       0.04       0.02       0.01       0.01       0.05       0.02         Total % at dose site       0.05       0.04       0.02       0.01       1.15       0.23         RECEPTOR COMPARIMENT         RECEPTOR COMPARIMENT         Receptor fluid (0-24h)       Ø.03       0.05       Ø.15       0.26       Ø.72       0.46         Receptor fluid terminal       n.d       0.002       0.006       0.04       0.03       0.03         Receptor chamber       n.d       0.03       0.02       0.006       0.04       0.03         Receptor chamber       n.d       0.03       0.03       0.05       0.17       0.04       0.25       0.17         Total % directly absorbed d       0.03       0.03       0.03       0.03       0.26       0.20       0.51         STUDY:       0.05       0.05       0.22       0.88       0.26       2.02       2.41         Total % Potentially Absorbatic c <td< td=""><td>Total % non-absorbed</td><td>102.8</td><td>°∼<b>5.8</b>1 ^</td><td>y 105.4</td><td>1.35</td><td>96,98</td><td>Q.78 🖉</td><td>¢`</td></td<>	Total % non-absorbed	102.8	°∼ <b>5.8</b> 1 ^	y 105.4	1.35	96,98	Q.78 🖉	¢`			
Skin b       Ø.02       Ø.04       Ø.07       0.064       Ø.96       2.00         Stratum corneum c       0.03       0.04       0.01       0.05       0.01       0.15       0.23         Total % at dose site       0.05       0.04       0.02       0.01       1.25       0.23         Receptor fluid (0-24h)       0.03       0.05       0.04       0.02       0.01       1.25       0.20         Receptor fluid (0-24h)       0.03       0.05       0.02       0.02       0.006       0.04       0.03         Receptor fluid terminal       n.d       0.02       0.002       0.006       0.04       0.03         Receptor chamber       n.d       0.03       0.05       0.02       0.004       0.05       0.17         Total % directly absorbed d       0.03       0.03       0.03       0.04       0.55       0.17         STUDY:       0.05       0.03       0.03       0.03       0.03       0.26       0.20       2.41         Total % Potentially Absorbative c       0.05       0.02       0.88       0.26       2.02       2.41	SKIN COMPARTMENT										
Stratum corneum c       0.03       0.04       0.01       0.01       0.15       0.23         Total % at dose site       0.05       0.04       0.02       0.01       1.15       0.23         RECEPTOR COMPARING NT         Receptor fluid (0-24h)       0.03       0.05       0.03       0.02       0.01       0.72       0.46         Receptor fluid terminal       n.d       0.02       0.002       0.06       0.04       0.03         Receptor chamber       n.d       0.03       0.03       0.04       0.05       0.17         Total % directly absorbed d       0.03       0.03       0.03       0.03       0.03       0.17       0.04       0.55       0.17         Total % directly absorbed d       0.03       0.03       0.03       0.03       0.24       0.26       0.26       0.05       0.17         Total % Potentially Absorbative       0.05       0.03       0.08       0.26       2.02       2.41         Total % Potentially Absorbative       0.05       0.05       0.02       0.88       0.26       2.02       2.41	Skin <sup>b</sup>	0.02	0.64	<u>~</u> 9.007 <sub>≪</sub>	0.004	Øð.96 🔬	≥ 2.0©				
Total % at dose site       0.05       0.04       0.02       0.01       1.05       42.01         RECEPTOR COMPARING VI         Receptor fluid (0-24h)       0.03       0.05       0.15       0.26       0.72       0.46         Receptor fluid terminal       n.d       0.002       0.002       0.006       0.04       0.03         Receptor chamber       n.d       0.002       0.004       0.05       0.17         Total % directly absorbed d       0.03       0.03       0.03       0.86       0.26       0.90       0.51         STUDY:       0.05       0.05       0.02       0.88       0.26       2.02       2.41	Stratum corneum <sup>c</sup>	0.03	0.04	S 0.01 T	6,01	S 0.15	<b>Ø</b> 23				
RECEPTOR COMPARTMENT         Receptor fluid (0-24h)       0.03       0.05       0.15       0.26       0.72       0.46         Receptor fluid terminal       n.d       0.002       0.002       0.004       0.03         Receptor fluid terminal       n.d       0.002       0.004       0.03         Receptor chamber       n.d       0.03       0.04       0.17         Total % directly absorbed d       0.03       0.03       0.86       0.26       0.90         STUDY:       0.05       0.02       0.88       0.26       2.02       2.41	Total % at dose site	0.05	0.04	0.02	00.01	1.10	<u>_</u> ≪Ž.01				
Receptor fluid (0-24h)       90.03       0.03       0.03       0.02       0.26       0.72       0.46         Receptor fluid terminal       n.d       0.002       0.002       0.004       0.03         Receptor chamber       n.d       0.01       0.01       0.04       0.03         Receptor chamber       n.d       0.03       0.03       0.04       0.15       0.17         Total % directly absorbed d       0.03       0.03       0.86       0.26       0.90       0.51         STUDY:       0.05       0.02       0.88       0.26       2.02       2.41         Total % Potentially Absorbatic       0.05       0.02       0.88       0.26       2.02       2.41	~~~	RECEPTO	<b>©COMPA</b>	RTMONT			<u>~~</u>				
Receptor fluid terminal       n.d.       0.002       0.002       0.006       0.04       0.03         Receptor chamber       n.d.       0.71       0.04       0.25       0.17         Total % directly absorbed d       0.03       0.03       0.86       0.26       0.90       0.51         STUDY:       0.05       0.05       0.02       0.88       0.26       2.02       2.41         Total % Potentially Absorbable       0.05       0.02       0.88       0.26       2.02       2.41	Receptor fluid (0-24h)	<u></u> \$€9.03	0.03	Ø.15 Q	0.26	°∂Ø.72 %	0.46				
Receptor chamber         n.d         0.71         0.04         0.55         0.17           Total % directly absorbed d         0.03         0.86         0.26         0.90         0.51           STUDY:         0.05         0.05         0.02         0.88         0.26         2.02         2.41           Total % Potentially Absorbable         0.05         0.02         0.88         0.26         2.02         2.41	Receptor fluid terminal	n.d		° <sup>%</sup> 0.002 <sup>©</sup>	_@@006	0.04 O	0.03				
Total % directly absorbed d $0.03$ $0.03$ $0.86$ $0.26$ $0.90$ $0.51$ STUDY: $0.05$ $0.02$ $0.86$ $0.26$ $2.02$ $2.41$ Total % Potentially Absorbable c $0.05$ $002$ $0.88$ $0.26$ $2.02$ $2.41$	Receptor chamber	n.d.	ay a	¢ 0.71♥	0.04	0.55	0.17				
STUDY: Total % Potentially Absorbable $0.05$ $002$ $0.88$ $0.26$ $2.02$ $2.41$	Total % directly absorbed d	<b>6</b> ,03	<u>&gt; 0.03 (</u>	<i>Q</i> .86	J <sup>V</sup> 0.26	<b>8.9</b> 0	0.51				
Total % Potentially Absorbable $\circ$ $\circ$ 0.05 $\circ$ 0.02 $\circ$ 0.88 $\circ$ 0.26 $\circ$ 2.02 2.41	STUDY:		<u> </u>	Ő <sup>Y</sup> & ,		6					
	Total % Potentially Absorbable °	0.05	002	× <u>→</u> 0.88	<u>(0</u> ,26 %	2.02	2.41				
101AL % KOKOVEKY 37 1020 35.80 7 100.5 01.36 7 98.99 4.32	TOTAL % RECOVERY	10209	<u>5</u> \$.80 _	106.3	O1.36 🕎	98.99	4.32				
Evaluation according to EFSA Guidance		aluation acco	rding toE	FSA Guidan	e 🖉						
absorption >7% within half of a start of the	absorption > 75% within half of	a St	L.Y	5° _0			<b>N</b> 7				
story duration v over v v v No No	stady duration	Yes West	s j y		0 .		No				
standard deviation $>25\%$ Yes $\sim$ Yes $\sim$ Yes	standard deviation >25%	Ye	sø 🗳		es@		Y es				
recovery < 95% v No No No	recovery <95%						INO				
Total % Potentially boorbastle f & 0.1 % 1 4	Total % Potentially tosorbable f	<u>رونی (0.1</u>	Ő		1		4				

<sup>a</sup>: sum of radioactivity found in swabs at termination and insurrounding swabs.
<sup>b</sup>: sum of radioactivity found in skin after tape-stripping procedule and in surrounding skin.
<sup>c</sup>: tape-strips excluding numbers 1 & which are considered to be non-absorbed dose.
<sup>d</sup>: sum of radioactivity found in receptor fluid (0-24h), receptor fluid terminal and receptor chamber.
<sup>e</sup>: total % directly absorbed + total % at Ose site
<sup>f</sup>: vatues considered for the adjusted Total % Potentially Absorbable according to EFSA are in *bold Italics*

SD: standard deviation

H.d.: not detected below the limit of detection)

n.a. : not applicable of a straight of a str

n: number of skin cells used for calculation In the above table the presented means do noralways calculate exactly from the presented individual data. This is the to rounding-the differences resoluting from the use of the spreadsheet program.

## **Conclusion:**

The dermal penetration through human dermatomed skin of  $[^{14}C]$ -fosetyl-Al in the FLC + FEA WG 71.11 formulation was investigated at three concentrations corresponding to the neat product (666.7 g fosetyl-Al/kg) and to two representative dilutions (20 and 2 g fosetyl-Al/L), respectively

The mean percentage of fosetyl-Al in the FLC + FEA WG 71.11 formulation that was considered to be potentially absorbable *(directly absorbed plus total remaining at dose site)* over a period of 24 hours for the neat formulation was 0.05% for the human skin. Applying the new EFSA guidance this value adjusts to 0.1%.

The mean percentage of fosetyl-Al in the FLC + FEA We 71.11 formulation that was considered to be potentially absorbable *(directly absorbed plus total remaining at dose site)* over a period of 24 hours of for the intermediate dose rate was 0.88% for human win. Applying the new EFSO guidance the value adjusts to 1%.

The mean percentage of fosetyl-Al in the FLC + FEA WG 71 Di formulation that was considered to be potentially absorbable *(directly absorbed plus total remaining at dose size)* over a period of 24 hours for the low dose rate was 2.0% for human skin. Applying the new EFSA guidance this value adjusts to 4%.

According to the new EFSA guidance<sup>3</sup> there is the provision that when the sampling period is 24 hours (which is the case for this study) and over 75% of the total absorption (material in the receptor fluid at the end of the study) occurred within half of the duration (12 hours) of the total sampling period that the absorption wall be taken as the sum of receptor fluid, receptor chamber washes and the skin sample excluding all tape strips. These criteria were met by the high group in this study. There is also the provision that a standard deviation equal to or larger than 25% of the mean of the absorption requires the use of an alternative value or rejection of the study. The guidance prefers the approach of adding the standard deviation to the mean to cover the upper 84<sup>th</sup> percentile value of the results. Additionally where an overall recovery of less than 5% occurs, a normalisation procedure is to be used by preference. Albert that the norifier considers that both the value of 25% for the standard deviation finit and the 95% recovery limit to be too conservative, the application of the guidance results in the following values for [4C]-fosetyl-AP in the 4LC + FEA WG 71.11 formulation:

- 0.1% for the neat formulation (666.7 Fosety/Al/kg)
- T% for the intermediate dose (20 stosety Al/L)
- 4% for the low dose (25 fosefyl-Al/K).

**CP 7.4 Available toxicological data relating to co-formulants** CONFIDENTIAL information, please refer to the respective Document JCP.

<sup>&</sup>lt;sup>13</sup> EFSA Panel on Plant Protection Products and their Residues (PPR); Guidance on Dermal Absorption. EFSA Journal 2012;10(4):2665. [30 pp.] doi:10.2903/j.efsa.2012.2665.